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Abstract
3-Nitrobenzanthrone (3-NBA) is a potent mutagen and suspected human carcinogen detected in diesel
exhaust and air pollution. It requires metabolic activation via nitroreduction to form DNA adducts and
promote mutagenesis. NAD(P)H:quinone oxidoreductase 1 (NQO1) was identified as the major
nitroreductase responsible for 3-NBA activation in liver, but this may not model inhalation exposures. I
sought to determine whether human aldo-keto reductase (AKR) enzymes could display novel
nitroreductase activity towards 3-NBA because they are widely expressed in the lung and AKR1C3
bioactivates nitroaromatic prodrug PR-104A. Using discontinuous enzymatic assays monitored by UVHPLC, I determined that AKR1C1-1C3 catalyze three successive 2-electron nitroreductions towards 3-NBA
to form the reduced product, 3-aminobenzanthrone. Evidence of the intermediates was obtained by UPLCHRMS. AKR1C1-1C3 and NQO1 have equivalent kcat/Km values and contribute equally to the
nitroreduction of 3-NBA in lung epithelial cell lines. Notably, AKR1C1-1C3 and NQO1 are induced by NF-E2
p45-related factor 2 (Nrf2) which raises the prospect that Nrf2-targeted chemopreventive agents may
exacerbate 3-NBA toxification. I examined 3-NBA bioactivation in adenocarcinomic human alveolar basal
epithelial (A549) cells which possess constitutively active Nrf2 signaling. To evaluate the role of Nrf2
signaling on this process, Nrf2 signaling was modulated by heterozygous (Nrf2-Het) and homozygous
Nrf2 knockout (Nrf2-KO). Pharmacological Nrf2 activators (sulforaphane, synthetic triterpenoids) were
evaluated in human bronchial epithelial cells (HBEC3-KT) which possess functional Nrf2 signaling.
Changes in AKR1C1-1C3 and NQO1 expression by Nrf2 knockout or use of Nrf2 activators were
confirmed by qPCR, immunoblots, and enzyme activity assays. I observed a reduction of 3-NBA
bioactivation in the A549 Nrf2 KO cell lines (53% reduction in A549 Nrf2-Het cells and 82% reduction in
A549 Nrf2-KO cells) and 40-60% increases in 3-NBA bioactivation due to Nrf2 inducers in HBEC3-KT cells.
Enhanced 3-NBA metabolic activation due to Nrf2 activity may increase DNA adducts and promote
mutagenesis. Nrf2 activation has been used as a chemopreventive strategy despite its increasingly
recognized potential to promote oncogenesis and chemotherapy resistance. Our data suggest that Nrf2
activation may also be deleterious in preventing cancer initiation for certain carcinogen exposures (i.e.
diesel exhaust) and should be utilized with caution.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Pharmacology

First Advisor
Trevor M. Penning

Keywords
3-nitrobenzanthrone, aldo-keto reductase, chemoprevention, metabolic activation, nitroarenes,
nitroreduction

Subject Categories
Biochemistry | Pharmacology | Toxicology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/3440

THE ROLE OF ALDO-KETO REDUCTASES AND NRF2 SIGNALING IN THE METABOLIC
ACTIVATION OF NITRATED POLYCYCLIC AROMATIC HYDROCARBONS

Jessica R. Murray
A DISSERTATION
in
Pharmacology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2019

Supervisor of Dissertation
_______________________
Trevor M. Penning
Molinoff Professor of Pharmacology

Graduate Group Chairperson
_______________________
Julie A. Blendy
Professor of Pharmacology

Dissertation Committee
Ian A. Blair, Ph.D., A.N. Richards Professor of Pharmacology
Harry Ischiropoulos, Ph.D, Research Professor of Pediatrics
Klaus H. Kaestner, Ph.D., Thomas and Evelyn Suor Butterworth Professor in Genetics
Anil Vachani, M.D., M.S., Associate Professor of Medicine

THE ROLE OF ALDO-KETO REDUCTASES AND NRF2 SIGNALING IN THE METABOLIC
ACTIVATION OF NITRATED POLYCYCLIC AROMATIC HYDROCARBONS
COPYRIGHT
2019
Jessica R. Murray

This work is licensed under the
Creative Commons AttributionNonCommercial-ShareAlike 3.0
License
To view a copy of this license, visit

https://creativecommons.org/licenses/by-nc-sa/3.0/us/

ACKNOWLEDGMENTS
First and foremost, I would like to sincerely thank my thesis advisor, Dr. Trevor M. Penning, for
his guidance and mentorship. His expertise, enthusiasm, and dedication to research are truly
inspirational. I am grateful that he always took the time to offer feedback and provide
opportunities for me to pursue my interests and challenge myself as a scientist. I would also like
to thank my committee members Drs. Ian A. Blair, Klaus Kaestner, Harry Ischiropoulos, and Anil
Vachani for their time, valuable suggestions, and support of this project.

I am grateful to the entire Penning lab, past and present, for their scientific input and support
throughout the years. It has been a joy to work along such talented and kind people. I am also
thankful for the numerous collaborators who made this work possible. Thank you to Dr.
Clementina Mesaros for her assistance with LC-HRMS analysis of 3-NBA metabolites. I would
also like to thank Dr. John D. Hayes for sponsoring my Erulkar Fellowship application to visit the
University of Dundee and gain a deeper understanding of Nrf2 signaling. Special thanks to Dr.
Laureano de la Vega for graciously sharing the A549 cell line variants.

Finally, I would like to thank my undergraduate mentors Drs. Margaret Saha and Mark Forsyth for
inspiring my love for research. I would not be here without them and I am forever grateful for all
the opportunities they gave me.

This work was supported by National Institute of Environmental Health Grants P30ES013508 and
T32019851, and a Pharmacology/Toxicology Pre-Doctoral Fellowship from the Pharmaceutical
Research and Manufacturers of America (PhRMA).

iii

ABSTRACT
THE ROLE OF ALDO-KETO REDUCTASES AND NRF2 SIGNALING IN THE METABOLIC
ACTIVATION OF NITRATED POLYCYCLIC AROMATIC HYDROCARBONS
Jessica R. Murray
Trevor M. Penning
3-Nitrobenzanthrone (3-NBA) is a potent mutagen and suspected human carcinogen detected in
diesel exhaust and air pollution. It requires metabolic activation via nitroreduction to form DNA
adducts and promote mutagenesis. NAD(P)H:quinone oxidoreductase 1 (NQO1) was identified
as the major nitroreductase responsible for 3-NBA activation in liver, but this may not model
inhalation exposures. I sought to determine whether human aldo-keto reductase (AKR) enzymes
could display novel nitroreductase activity towards 3-NBA because they are widely expressed in
the lung and AKR1C3 bioactivates nitroaromatic prodrug PR-104A. Using discontinuous
enzymatic assays monitored by UV-HPLC, I determined that AKR1C1-1C3 catalyze three
successive 2-electron nitroreductions towards 3-NBA to form the reduced product, 3aminobenzanthrone. Evidence of the intermediates was obtained by UPLC-HRMS. AKR1C1-1C3
and NQO1 have equivalent kcat/Km values and contribute equally to the nitroreduction of 3-NBA in
lung epithelial cell lines. Notably, AKR1C1-1C3 and NQO1 are induced by NF-E2 p45-related
factor 2 (Nrf2) which raises the prospect that Nrf2-targeted chemopreventive agents may
exacerbate 3-NBA toxification. I examined 3-NBA bioactivation in adenocarcinomic human
alveolar basal epithelial (A549) cells which possess constitutively active Nrf2 signaling. To
evaluate the role of Nrf2 signaling on this process, Nrf2 signaling was modulated by heterozygous
(Nrf2-Het) and homozygous Nrf2 knockout (Nrf2-KO). Pharmacological Nrf2 activators
(sulforaphane, synthetic triterpenoids) were evaluated in human bronchial epithelial cells
(HBEC3-KT) which possess functional Nrf2 signaling. Changes in AKR1C1-1C3 and NQO1
expression by Nrf2 knockout or use of Nrf2 activators were confirmed by qPCR, immunoblots,
and enzyme activity assays. I observed a reduction of 3-NBA bioactivation in the A549 Nrf2 KO
cell lines (53% reduction in A549 Nrf2-Het cells and 82% reduction in A549 Nrf2-KO cells) and
40-60% increases in 3-NBA bioactivation due to Nrf2 inducers in HBEC3-KT cells. Enhanced 3-

iv

NBA metabolic activation due to Nrf2 activity may increase DNA adducts and promote
mutagenesis. Nrf2 activation has been used as a chemopreventive strategy despite its
increasingly recognized potential to promote oncogenesis and chemotherapy resistance. Our
data suggest that Nrf2 activation may also be deleterious in preventing cancer initiation for certain
carcinogen exposures (i.e. diesel exhaust) and should be utilized with caution.
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1. INTRODUCTION
This thesis focuses on the metabolic activation of nitrated polycyclic aromatic
hydrocarbons (NO2-PAHs) by novel nitroreductase activity of human aldo-keto
reductases and how Nrf2-targeted chemopreventive strategies may impact this process. In
this introduction, I provide a brief overview of the importance of nitroreduction and the
mechanisms by which it can occur; an introduction to NO2-PAHs and their relevance to
human lung cancer; an overview of the human aldo-keto reductase superfamily; and an
introduction to Nrf2-Keap1 signaling and how it relates to chemoprevention and cancer
promotion.
1.1
1.1.1

Enzymatic Nitroreduction

Introduction to Nitroreductases
Nitro-substituted compounds such as nitroaromatic and nitroheterocyclic

derivatives comprise a large class of chemicals that are characterized by the presence of
one or more nitro (NO2) groups. These include nitrofurans, nitropyrenes, nitrobenzenes,
nitrofluorenes, and nitroarenes, among others. Nitroaromatic compounds are widely used
as chemotherapeutic agents, antimicrobial agents, food additives, pesticides, explosives,
dyes, and chemical intermediates in industrial synthesis.1-2 They are also concentrated in
diesel engine exhaust (DEE) and contribute to urban air pollution.3-5 As a result, they are
broadly distributed in the environment which presents a considerable public health threat
as many of these compounds are toxic, mutagenic, and/or suspected carcinogens.3, 6-7
Enzymatic reduction by nitroreductases is essential for these compounds to exert
their cytotoxic and mutagenic effects.8-12 Nitroreductases are primarily flavin
mononucleotide (FMN)- or flavin adenine dinucleotide (FAD)-dependent enzymes that
1

reduce nitro-substituted compounds using nicotinamide adenine dinucleotide (NAD(P)H
or NADH). They can be broadly classified into two groups: oxygen-insensitive (Type I)
and oxygen-sensitive (Type II).13
Type I nitroreductases catalyze three successive two-electron transfers to the nitro
group in the presence or absence of oxygen, resulting in nitroso (NO) and hydroxylamino
(NHOH) intermediates and the fully reduced amine (NH2) product.9, 13 The predominant
product of this reaction may be the hydroxylamino or the amine, depending on the
nitroreductase and the structure of the compound.14-15 These reactions typically proceed
via a ping-pong, bi-bi kinetic mechanism, and the FMN or FAD group cycles between the
oxidized and reduced states.9 The nitroso intermediate is rarely isolated because it is
highly reactive and the second two-electron reaction proceeds much faster than the initial
two-electron reduction.9 Bacterial nitroreductases reduce the nitroso intermediates with
catalytic efficiencies (kcat/Km) approximately 10,000-fold greater than that of the parent
nitro compounds, which explains why the nitroso intermediates are not usually
detected.8 The hydroxylamino intermediate is stable in numerous studies and can interact
directly with biological macromolecules leading to cell and DNA damage, or it can
undergo further processing to generate cytotoxic agents.16-17 Type I nitroreductases were
first identified in Escherichia coli (E. coli) and are predominantly found in enteric
bacteria, including Salmonella typhimurium, Enterobacter cloacae, and Clostridium
acetobutylicum, among others.18-19 Type I bacterial nitroreductases can be classified into
two main groups or families, according to their similarity with E.coli nitroreductases:
NfsA (group A) which use NADPH as an electron source and NfsB (group B) which can
use either NADH or NADPH.18-19 Nitroreduction by the intestinal microflora is thought

2

to play an important role in the toxicity of several nitroaromatic compounds.20 A limited
number of mammalian Type I nitroreductases have also been identified. NAD(P)Hquinone oxidoreductase (NQO1) is the most frequently described mammalian
nitroreductase which typically catalyzes reduction of quinones.21-22 Xanthine oxidase
(XO) also displays nitroreductase activity, but typically catalyzes the oxidation of
hypoxanthine to xanthine, and can further oxidize xanthine to uric acid.23
Oxygen-sensitive type II nitroreductases mediate a one-electron reduction of the
nitro group, producing a nitroanion radical. These enzymes are oxygen-sensitive, because
the resulting radicals are easily re-oxidized to the parent compounds by O2 in a futile
redox cycle which generates superoxide and promotes oxidative cell damage. Thus, these
enzymes only mediate the complete reduction of nitroaromatics under anaerobic
conditions.13,

16, 24-25

Several mammalian Type II nitroreductases have been identified,

including nitric oxide synthase,26 cytochrome b5 reductase,27 aldehyde oxidase,13 and
cytochrome P-450 oxidoreductase (POR).28-29

3

Figure 1.1 Mechanism of Type I and Type II nitroreductases on representative
nitroaromatic compound, nitrobenzene (1). Type I nitroreductases catalyze up to three
successive two-electron reductions to form the nitroso (2) and hydroxylamino (3)
intermediates and the amine (4) product. Type II nitroreductases catalyze one-electron
reductions which generates a nitroanion radical (5) and hydronitroxide radical (6). In the
presence of oxygen, superoxide anion is produced in a futile redox cycle, regenerating the
parent compound.

4

1.1.2

Clinical Relevance of Nitroreductases
Nitroreductases have been extensively characterized for their potential to activate

prodrugs in directed chemotherapies. Although chemotherapy remains an important
treatment option for cancer patients, its success is limited by lack of tumor specificity and
systemic toxicity because the doses required to reach therapeutic levels in the tumor are
often cytotoxic to healthy tissues.30 Enzyme prodrug therapy is a promising strategy to
minimize off-target toxicities. Prodrugs are nontoxic but can be converted to highly
cytotoxic species at the desired location by targeted expression of bioactivating enzymes
within the tumors.31-32

Nitroaromatic compounds represent the largest class of

bioreductive prodrugs, which includes oxygen-sensitive and oxygen-insensitive
compounds that remain pharmacodynamically inert until they are reduced to
hydroxylamines which will damage DNA and cause cell death.15 Antibody-directed
enzyme prodrug therapy (ADEPT)15,

33

and gene- (or virus-) directed enzyme prodrug

therapy (GDEPT, or VDEPT)34-35 have been developed to deliver an oxygen-insensitive
E. coli nitroreductase to tumors which effectively activates many nitroaromatic
prodrugs.15

CB1954

(5-aziridinyl

2,4-dinitrobenzamide)

is

the

prototype

of

the

dinitrobenzamide family of prodrugs which are activated by Type I nitroreductases.
CB1954 has received notable attention because it caused complete regression of the
Walker-256 carcinoma tumor in rats with minimal toxic side effects.36 This was later
attributed to overexpression of NQO1 in rat tumors which efficiently catalyzed
successive two-electron reductions to form the cytotoxic hydroxylamine. This compound
was initially unsuccessful in humans because human NQO1 was much less efficient for
5

the bioactivation of CB1954 than the rat enzyme, but it has been used in combination
with ADEPT and GDEPT therapies.37 Additionally, other prodrug substrates for bacterial
nitroreductases have been tested and developed, including various oxazino-acridines,
dinitrobenzamide mustards, nitrobenzyl derivatives, and nitroheterocyclic carbamates.30

Nitroaromatic compounds that preferentially undergo one-electron nitroreduction
are also of clinical importance and have also been exploited as hypoxia-selective imaging
agents and cytotoxins.38 Oxygen-sensitive compounds possess natural selectivity for
anaerobic solid tumors because they are activated by one-electron reduction steps which
is inhibited by the presence of molecular oxygen.38 PR-104A is a dinitrobenzamide
mustard that was developed as a hypoxic chemotherapy that would be activated by Type
II nitroreductases to form potent DNA crosslinking agents: hydroxylamine PR-104H and
amine PR-104M. Over 60% of the one-electron nitroreduction in anaerobic tumors was
attributed to POR.39 Development of this compound was complicated by the observation
that PR-104A could also undergo aerobic metabolism which was not attributed to NQO1.
Guise and colleagues were the first to report that human aldo-keto reductase 1C3
(AKR1C3) could activate PR-104A to hydroxylamine PR-104H and amine PR-104M via
nitroreduction.38 This observation was surprising given that AKR1C3 is a carbonyl
reductase and has not been previously characterized as a nitroreductase. AKR1C3 failed
to activate a panel of other bioreductive prodrugs, indicating it possesses high substrate
specificity for PR-104A.38 Although AKR1C3 failed to act as a general nitroreductase in
this study, it raises questions about 1) its potential to act as a reductase towards other
nitroaromatic compounds that were not included in this study and 2) which mammalian
enzymes have yet to be characterized as Type I nitroreductases.
6

1.1.3

Relevance of Nitroreductases to Environmental Health
Under the right circumstances, nitroaromatic compounds can be successfully used

as chemotherapeutic agents when coupled to tumor-specific expression of exogenous
nitroreductases via directed enzyme prodrug therapy (DEPT). However, endogenous
nitroreductases can lead to cancer initiation when humans are environmentally exposed to
pro-carcinogens that contain a nitro group. Nitroreduction leads to the formation of
hydroxylamino intermediates which undergo subsequent activation to form DNA adducts
and promote oxidative stress in healthy cells. Metabolic activation of these carcinogens to
reactive DNA- and protein-binding intermediates is associated with toxicity,
mutagenesis, and carcinogenesis. If not repaired, covalent DNA adducts or oxidative
lesions may promote GT or AT transversions in oncogenes (K-Ras, H-Ras, N-Ras)
or tumor suppressors (TP53) which leads to cancer initiation.40-42 Initiation is an
irreversible event and occurs when mutations arise in critical oncogenes which control
cell proliferation.43 Notable examples of nitroaromatic carcinogens include the nitropolycyclic aromatic hydrocarbons (NO2-PAHs) which will be the primary focus of this
thesis,44 as well as aristolochic acids45-46 and nitrobenzene derivatives.47
Understanding which human enzymes are involved in the bioactivation and/or
detoxication of these compounds is important in the assessment of an individual's
susceptibility to nitroaromatic carcinogens. NQO1 has long been suspected to be the
major nitroreductase that activates these carcinogens in humans, but multiple studies
suggest that others could be important as well. The prodrug CB1954 was promising in
rats, but clinical trials in humans revealed unacceptable liver toxicity due to endogenous
nitroreductases.48-49 Human liver preparations activated CB1954 to the DNA cross-
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linking 4-hydroxylamino and 4-amine metabolites which are 200-fold more toxic than the
parent compound, but this could not be attributed to NQO1 or POR.49-50 This indicates
that unidentified nitroreductases are present in the human liver. Likewise, many
laboratories are currently investigating which human nitroreductases are able to
bioactivate aristolochic acids, carcinogenic and nephrotoxic plant alkaloids present in
Aristolochia species that contaminate food products and are used in traditional medicine.
There is great interest in identifying the major nitroreductase responsible given that these
agents cause Balkan endemic nephropathy, a severe kidney disease that results in chronic
renal failure and urothelial carcinoma of the upper urinary tract.46
1.2
1.2.1

Nitrated Polycyclic Aromatic Hydrocarbons

Introduction
Nitrated polycyclic aromatic hydrocarbons (NO2-PAHs) are a large class of

structurally related chemicals found in particulate emissions from several combustion
sources, most notably diesel engine exhaust (DEE).51 NO2-PAHs are nitro-substituted
derivatives of polycyclic aromatic hydrocarbons (PAHs) with at least one nitro group
covalently bound to a cyclic carbon atom and can also be classified as nitroarenes. NO2PAHs possess cytotoxic, mutagenic, and tumorigenic properties in vitro and in animal
models once they undergo metabolic activation via nitroreduction. The parent
compounds, PAHs, have been thoroughly characterized and are recognized as human
carcinogens which drive the tumorigenic activity of tobacco smoke and air pollution.43, 5253

Some NO2-PAHs are classified as possible or probable human carcinogens by the

International Agency for Research on Cancer (IARC), but for many of these compounds
limited data are available, which makes their evaluation difficult. The cytotoxic and
8

mutagenic effects of several NO2-PAHs are more pronounced than that of
benzo[a]pyrene (B[a]P), the only PAH which has sufficient evidence to be classified as a
Group 1 human carcinogen by IARC.54-56 For example, the most mutagenic compound
ever described to date is 3-nitrobenzanthrone (3-NBA), which causes 20,000-fold to
50,000-fold more mutations per nmol in the Salmonella typhimurium Ames assay than
B[a]P, a known human carcinogen implicated in tobacco carcinogenesis.57-58 The second
most mutagenic compound described is 1,8-dinitropyrene, indicating that multiple NO2PAHs are potent mutagens and warrant further study to elucidate the nitroreductases
responsible for their toxication.58 These compounds are also potent lung tumorigens. 6Nitrochrysene (6-NC) has been reported to be the most potent lung and liver carcinogen
ever described in the newborn mouse tumorigenesis assay.59-60
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Figure 1.2. Structure of B[a]P and representative NO2-PAHs.
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1.2.2

Environmental Occurrence
NO2-PAHs are ubiquitous environmental pollutants generated by incomplete

combustion of fossil fuels and by atmospheric reactions of unsubstituted PAHs with
hydroxyl (OH) and nitrate (NO3) radicals in the presence of NOx.61-62 They are detected
in vapor phases and particulate matter of air pollution but these compounds are not
routinely monitored.63 NO2-PAHs are primarily produced in emissions from diesel and
gasoline engines, but they are emitted from diesel engines at 10-fold higher
concentrations than from gasoline engines.4,

64-68

Unsubstituted PAHs are also major

products of incomplete combustion and can be converted into NO2-PAHs via
reactions with atmospheric oxidants (OH, O3, NOx).62,

69-70

The main atmospheric

reaction pathway that forms NO2-PAHs is initiated by OH-radicals which are generated
by photolysis of ozone and water.56
NO2-PAHs are elevated in urban air pollution and near roadways due to DEE.62 The
IARC has recently listed DEE as a known human carcinogen and has classified several
NO2-PAHs detected in the particulate and gaseous phases of DEE as probable or possible
human carcinogens (Table 1.1).71 NO2-PAHs are usually detected in the environment in
the range of several pg m− 3 to a few ng m− 3, which are about 1 – 3 orders of magnitude
lower than those of related PAHs.72-73 NO2-PAHs adhered to superfine particulate matter
can accumulate in the epithelia of trachea and bronchial regions of exposed lung tissue,
resulting in high local exposures in the context of low environmental concentrations.74
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Table 1.1. NO2-PAHs detected in the gaseous and particulate phases of
diesel engine exhaust
Compound
IARC Rankinga
3,7-Dinitrofluoranthene
2B
3,9-Dinitrofluoranthene
2B
1,3-Dinitropyrene
2B
1,6-Dinitropyrene
2B
1,8-Dinitropyrene
2B
3-Nitrobenzanthrone
2B
6-Nitrochrysene
2A
2-Nitrofluorene
2B
1-Nitropyrene
2A
4-Nitropyrene
2B
a
4
Data from IARC Monograph. The IARC uses the following ranking system
to classify carcinogens: Group 1: carcinogenic to humans; Group 2A: probably
carcinogenic to humans; Group 2B: possibly carcinogenic to humans; Group 3:
unclassifiable as to carcinogenicity in humans; and Group 4: probably not
carcinogenic to humans.
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1.2.3

Diesel Engine Exhaust and Lung Cancer
Decades of epidemiologic research have shown that exposure to DEE increases

the incidence of lung cancers in humans.4 Lung cancer is the leading cause of cancerrelated death in both men and women in the United States and worldwide, and was
responsible for over 1.7 million deaths worldwide in 2018.75 Approximately 90% of the
annual lung cancer incidence burden is attributed to tobacco smoking, but environmental
air pollutants such as DEE and air pollution increase lung cancer risk in nonsmokers.
DEE increased lung cancer incidence in railroad workers, mechanics, professional
drivers, construction workers, and miners.4, 76-78 A linear dose-response relationship exists
between exposure to DEE and lung cancer risk in many of these studies.79-80 Miners with
the most extensive exposure to DEE experienced a risk of lung cancer that was threetimes greater than workers with the lowest exposure to DEE,76 and increased duration to
DEE increased lung cancer mortality.81 Lung cancer mortality is also attributed to DEE.
Occupational exposures to 1 and 25 μg m-3 elemental carbon (EC), a proxy measure of
DEE, are estimated to lead to an additional 17 to 689 deaths per 10,000.82
A meta-regression analysis of lung cancer mortality estimated that 21 excess lung
cancer deaths per 10,000 in the general population are due to low, environmental
exposures to diesel exhaust.82 The attributable fraction of lung cancers due to exposure to
DEE either in the environmental or occupational setting is approximately 6% based on
estimated lifetime exposures in the United States and United Kingdom.82 Another
prospective study estimated that 5-7% of lung cancers in European never-smokers and
ex-smokers are attributable to high levels of air pollution and proximity to heavy traffic
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roadways.83 The total population attributable fraction of lung cancer due to occupational
diesel exhaust was lower in Canada and was estimated to be approximately 2.4%.84
DEE is a complex mixture of many known and suspected carcinogens. However,
further characterization of the carcinogenic potential of NO2-PAHs may be essential to
understand and minimize cancer risks for those who operate heavy machinery, drive
diesel-powered equipment, or live near roadways or urban areas.81, 85 The direct-acting
mutagenicity of DEE fractions containing NO2-PAHs is 200% higher than fractions
lacking NO2-PAHs in air particulate samples from China, indicating that it is important to
monitor NO2-PAHs to accurately estimate mutagenic properties of air pollution and
corresponding human health risks.86 A separate study found that mono- and dinitro-PAHs
account for 30 – 40% of the bacterial mutagenic activity of DEE particulate matter.87
NO2-PAHs have been detected in the lungs of non-smokers with lung cancer indicating
that 1) humans are exposed to these compounds and 2) these compounds may be related
to lung cancer causation.44, 51
1.2.4

Metabolic Activation of NO2-PAHs
NO2-PAHs are classified as either Group 2A or 2B carcinogens by the IARC and

are potent lung tumorigens in rodents.4 Metabolic activation of NO2-PAHs is required to
exert their mutagenic and tumorigenic effects. NO2-PAHs may be bioactivated by ring
oxidation, nitroreduction, or both. Although nitroreduction is the focus of this study, ring
oxidation represents an important activation step and will be briefly described by
considering the bioactivation of three representative compounds: 1-NP, 6-NC, and 3NBA. Ring oxidation is critical for the eventual detoxification of 1-NP and 6-NC, while
nitroreduction leads to bulky DNA adduct formation for 1-NP, 6-NC, and 3-NBA.
14

Human biomonitoring studies have reported higher levels of bulky DNA adducts among
individuals with high exposures to diesel exhaust and urban air pollution which correlates
with an increased cancer risk, so it is important to consider which metabolic pathways
lead to DNA adduct formation.88-89
Ring oxidation is catalyzed by cytochromes P450 (P450) isozymes which gives
rise to epoxides, phenols, and dihydrodiols in a structure-dependent manner. For
example, 1-nitropyrene (1-NP) undergoes P450-mediated hydroxylation to form phenols,
but monooxygenation of 6-NC leads to the formation of epoxides and dihydrodiols
(Figure 1.3). 3-NBA does not undergo P450-mediated monooxygenation which is likely
due to the presence of the ketone group. This may be representative for other nitro-oxyPAHs.
As introduced above, nitroreduction is catalyzed by Type I and Type II
mammalian nitroreductases (NQO1 and POR, respectively) and proceeds through three
successive two-electron reductions to yield the nitroso (NO), hydroxylamino (NHOH),
and amino (NH2) derivatives.44,

90

The hydroxylamino intermediate undergoes

esterification which provides a good leaving group, giving rise to a nitrenium ion which
binds DNA and forms stable DNA adducts.
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Figure 1.3. Ring oxidation and nitroreduction contribute to metabolism of NO2-PAHs, using 1-NP as an example.
Abbreviations: 1-NOP, 1-nitrosopyrene; N-OH-1-AP, N-hydroxy-1-aminopyrene; 1-AP, 1-aminopyrene; hydroxy-1-NP, hydroxylated
metabolites of 1-NP; hydroxy-1-AP, hydroxylated metabolites of 1-AP.

NO2-PAHs that undergo monooxygenation can form dihydrodiols in a similar
fashion as unsubstituted PAHs which is best demonstrated using 6-NC as a representative
NO2-PAH with a bay region. 6-NC is metabolically activated to trans-1,2-dihydro-1,2dihydroxy-6-nitrochrysene (trans-6-NC-1,2-dihydrodiol) and trans-1,2-dihydro-1,2dihydroxy-6-aminochrysene (trans-6-AC-1,2-dihydrodiol) in rodents.91-92 trans-6-NC1,2-dihydrodiol is also the major metabolite of 6-NC in primary human breast cells and in
human hepatic and pulmonary microsomal reactions.93 Oxidation of 6-NC to form the
dihydrodiol is primarily attributed to P4501A2 in human liver and P4501A1 in human
lung.94 trans-6-AC-1,2-dihydrodiol is formed in MCF-7 breast cells treated with 6-NC,
indicating that both nitroreduction and monooxygenation occurs in humans.
The

trans-6-NC-1,2-dihydrodiol-3,4-oxide

(anti-1,2-dihydroxy-3,4-epoxy-

1,2,3,4-tetrahydro-6-nitrochrysene, 6-NCDE) was proposed as the ultimate carcinogen
derived from 6-NC (Figure 1.4). This prediction was based on the observation that PAH
diol epoxides are the ultimate carcinogens that bind DNA and form stable mutagenic
DNA adducts. Incubation of 6-NCDE with calf thymus DNA, dGuo, or dAdo gave diol
epoxide DNA adducts as expected, but these adducts were not detected in rat liver
following 6-NC treatment. It was concluded that the diol epoxide did not contribute to the
mutagenic and tumorigenic properties of 6-NC.95 Major 6-NC DNA adducts observed in
vivo were derived from 6-hydroxylaminochrysene and 6-hydroxylaminochrysene-1,2dihydrodiol and were identified as 6-AC-N2-dGuo [N2-(6-aminochrysen-5-yl)-2’deoxyguanine]

and

6-AC-1,2-DHD-N2-dGuo

[N2-(6-AC-1,2-dihydrodiol-5-yl)-2’-

deoxyguanine], respectively, suggesting that nitroreduction is required to promote DNA
adduct formation even when ring oxidation occurs.91, 96

17

DNA Adducts

DNA Adducts
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Figure 1.4. Metabolic activation of NO2-PAHs, using 6-NC as an example. Ring oxidation of 6-NC does not lead to formation of
diol epoxides and subsequent DNA adducts. Nitroreduction is required for DNA adduct formation. Red arrows indicate that these
proposed steps do not lead to DNA adduct formation in vivo.

The metabolic activation of NO2-PAHs involving nitroreduction and subsequent
O-esterification to form DNA adducts is best exemplified using 3-NBA. 3-NBA is
activated to N-hydroxy-3-aminobenzanthrone (N-OH-3-ABA) which is further activated
by conjugation enzymes, including N,O-acetyltransferases (NAT1, 2) and SULTs
(SULT1A2, 1A2) leading to the formation of reactive N-acetoxy- or sulfooxy- esters
(Figure 1.5). DNA binding is predicted to occur via an aryl nitrenium ion, formed
through heterolytic cleavage of ester metabolites.44 The fully reduced amine, 3aminobenzanthrone (3-ABA) is also formed and may be oxidized back to N-OH-3-ABA
or may directly give rise to nitrenium ions via human myeloperoxidase (MPO),
lactoperoxidase, and prostaglandin H synthase.97
Possible nitroreductases involved in this reaction include NQO1, XO, and POR.23,
98-101

Cytosolic NQO1 is considered the primary enzyme responsible for the

nitroreduction of 3-NBA based on experiments using the NQO1-specific inhibitor
dicoumarol in human hepatocytes, rat liver extracts, and human recombinant NQO1.98,
102-104

The role of POR as a nitroreductase in vivo is likely limited since no differences in

DNA adduct formation were observed between wildtype and hepatic POR null mice.44
These mice had fewer DNA adducts when administered 3-ABA, indicating that hepatic
P450 enzymes contribute to formation of N-OH-3-ABA via 3-ABA oxidation, but the
primary mechanism of activation is via reduction of 3-NBA to form the hydroxylamino
compound. Human P4501A1 and 1A2 are the major monooxygenases which catalyze
formation of N-OH-ABA from 3-ABA, while P4502A6, 3A4, and 2B6 also contribute.97,
100-101, 103
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Figure 1.5. Nitroreduction of NO2-PAHs, using 3-NBA as example. Abbreviations used: NQO1, NAD(P)H:quinone oxidoreductase
1; NAT1/2, N,O-acetyltransferase isozymes; SULT1A1/1A2, sulfotransferases 1A1 and 1A2; P450, cytochrome P450; MPO,
myeloperoxidase. Modified from Arlt et al., 2006.97

1.2.5

Detoxification of NO2-PAHs
NO2-PAHs that first undergo monooxygenation by P450s (1-NP, 6-NC, 2-

nitrofluorene) are primarily excreted in urine as glucuronide or sulfate conjugates.90-91, 105
The UGT and SULT isoforms responsible have not been identified. The route of
detoxification of 1-NP appears to be dependent upon the position of monooxygenation.
The majority of 1-NP is oxidized to form 1-NP-4,5-oxide which is primarily hydrolyzed
to the corresponding dihydrodiol and excreted as glucuronide conjugates.106 On the other
hand, minor amounts of 1-NP-9,10-oxide are formed and are primarily detoxified by
GSH conjugation. By contrast, 3-NBA does not undergo P450 monooxygenation. Phase
II conjugation reactions are integral to its metabolic activation. NATs and SULTs form
reactive esters which contribute to the formation of the nitrenium ion and subsequent
DNA adduct formation.98, 107 This may be a contributing factor to the high mutagenicity
of 3-NBA.
1.2.6

3-Nitrobenzanthrone: “The Devil in the Diesel”
3-NBA is the most mutagenic compound described to date and promotes lung

squamous cell carcinoma and adenocarcinomas in murine models.108 The popular press
has described it as the “devil in the diesel” based on its mutagenic properties.44 It is
currently classified as a Group 2B by the IARC which designates it as possible human
carcinogen. It is important to note that this does not indicate it is less harmful than Group
1 carcinogens such as B[a]P. 3-NBA and several other NO2-PAHs have greater toxic
equivalency factors (TEFs) than B[a]P which indicates that they warrant further
investigation to fully evaluate human risk due to DEE exposures. The mutational
spectrum following exposure to 3-NBA in mice is very similar to the GT transversions
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observed in lungs of gpt delta mice following inhalation of DEE, indicating that 3-NBA
may be a major contributor to DEE-induced carcinogenesis.42
3-NBA has been detected at concentrations up to 6.6 µg g-1 in particulate matter
from diesel exhaust.109 Airborne concentrations are lower, and are usally at the order of
several picograms per cubic meter: up to 11.5 pg m-3 in urban areas and up to 80 pg m-3
in workplaces with high exposure to diesel exhaust.110 This is much lower than the most
abundant NO2-PAH, 1-NP, which is detected at levels up to 39.64 µg g-1 in particulate
matter from diesel exhaust.73
Despite its low concentration, 3-NBA warrants further investigation due to its
elevated mutagenicity. 3-NBA induces approximately 0.2 and 6 million revertants per
nmol in the Ames Salmonella assay in strains TA98 and YG1024 without S9 activation,
respectively.109 3-NBA promotes mutagenesis by forming bulky DNA adducts following
metabolic activaation. 3-NBA-derived DNA adducts ultimately form at the C8 and
N2 position of guanine and at the C8 and N6 position of adenine in vitro and in vivo.111
Major adducts formed in vivo include 3-ABA-N2-dGuo [N2-(3-aminobenzanthron-2-yl)3-ABA-N6-dAdo

2’-deoxyguanosine],
deoxyadenosine],

and

3-ABA-N-C8-dGuo

[N6-(3-aminobenzanthron-2-yl)-2’[C8-(3-aminobenzanthron-N-yl)-2’-

deoxyguanosine], see Figure 1.6.112 In vivo studies report that adducts form in the small
intestine, stomach, liver, kidney, and lungs following oral, intraperitoneal, and
intratracheal administration of 3-NBA.71 DNA adducts have been primarily identified by
32

P-postlabelling using thin layer chromatography (TLC), but the formation of three

major DNA adducts in animal models has been validated by HPLC-MS/MS with stable
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isotope labeled internal standards.113 These characteristic DNA adducts are also seen in
lung A549, liver HepG2, colon HCT116, and breast MCF-7 cells.114-115
3-NBA induced mainly GT transversions in the cII gene within livers of the
transgenic Muta™Mouse, which is consistent with the extensive formation of 3-ABAN2-dGuo and 3-ABA-N-C8-dGuo adducts.116 A dose-dependent increase in lacZ mutant
frequency due to 3-NBA treatment was observed when using the Muta™Mouse in
vivo117-118 and Muta™Mouse FE1 lung epithelial cells exposed in vitro.118 In these test
systems, the 3-NBA mutation spectrum is very similar to the GT transversions
observed in the lungs of gpt delta mice following inhalation of DEE.42
3-NBA treatment also induces GT transversions in human TP53 mutational
hotspots when using the human-TP53 knock-in murine embryonic fibroblasts (HUF)
immortalization assay. These observed mutations closely mirror TP53 hotspot mutations
in smokers. The most frequently mutated TP53 hotspot codons in smokers lung cancer
(157, 158, 175, 179, 245, 248, 249, 273, 282) or cancer in general (175, 245, 248, 249,
273, 282) were mutated following 3-NBA treatment.119 Four codons have been targeted
in multiple studies with 3-NBA, including 236, 244, 245, and 273.119-120 These studies
have observed minimal overlap with B[a]P diol epoxide-induced mutations in (157, 158,
245, 248, and 273), which supports the notion that a chemical carcinogen’s binding
efficiency or DNA adduct repair efficiency drives its mutational spectrum.119 However,
these mutational signatures may also be driven by biological selection.121
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Figure 1.6. Major DNA adducts derived from 3-NBA in vivo.
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1.3
1.3.1

Aldo-keto Reductases

AKR Superfamily
Oxidoreductase enzymes can be organized into three superfamilies – the medium-

chain alcohol dehydrogenases, short-chain dehydrogenases/reductases, and the aldo-keto
reductases.122-123 Aldo-keto reductases (AKRs) are a major superfamily of NAD(P)Hdependent oxidoreductases that possess the ability to convert aldehydes and ketones to
primary and secondary alcohols and are present in all phyla.124-125 AKRs catalyze an
ordered bi-bi kinetic mechanism which is characterized by the NAD(P)H cofactor
binding before the substrate carbonyl, and then the ordered release of the alcohol and
NAD(P)+ products, respectively.126-127
The AKR superfamily contains over 190 members which are further divided into
16 families.124, 128 The nomenclature of this enzyme superfamily is derived from sequence
alignment whereby related members are grouped based on enzyme function. Enzymes
with at least 40% similarity are classified as family members, and enzymes with greater
than 60% sequence similarity are grouped into a subfamily. Protein members within a
subfamily are identified with numerals.129 There are currently 15 human AKR
members.128 These include aldehyde reductase (AKR1A1); aldose reductase-related
proteins (AKR1B1, AKR1B10 and AKR1B15); hydroxysteroid dehydrogenases
(AKR1C1-AKR1C4); steroid 5β-reductase (AKR1D1); 1,5-anhydro-D-fructose reductase
(AKR1E2); the β-subunits of the potassium voltage gated channels (AKR6A3, AKR6A5,
and AKR6A9); and dimeric aflatoxin aldehyde reductases (AKR7A2 and AKR7A3).
Human AKRs are primarily monomeric, soluble proteins (37 kDa) possessing a
(α/β)8-barrel motif, display large loops at the back of the barrel which influence substrate
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specificity, and share a conserved cofactor binding domain.130-131 These enzymes have
broad substrate specificity and reduce several carbonyl substrates, including sugar
aldehydes, keto-steroids, keto-prostaglandins, retinals, quinones, and lipid peroxidation
byproducts.132 These enzymes have been previously implicated in carcinogen
bioactivation, including nicotine derived nitrosamines,133 PAH metabolites,134 and
aflatoxin dialdehyde.135 Despite the observation that AKRs catalyze oxidoreduction in
vitro, they primarily function as reductases in vivo since they display nanomolar affinity
for NADPH with Kd values in the range of 10 – 120 nM.136 A notable exception is the
oxidation of trans-dihydrodiol PAHs.124,

134

Human AKR1C3 displays nitroreductase

activity towards the nitroaromatic prodrug PR-104A, but failed to activate a panel of
other nitroaromatic compounds in the same study.38-39 This finding highlights the
potential that AKRs may act as nitroreductases for a select group of nitroaromatic
compounds.
1.3.2

The Hydroxysteroid Dehydrogenases (AKR1C1-AKR1C4)
The human isoforms of the AKR1C hydroxysteroid dehydrogenase (HSD)/

dihydrodiol dehydrogenases (DD) subfamily include AKR1C1–1C4. AKR1C1–1C3 are
widely expressed in human tissues while AKR1C4 is liver specific.137 These enzymes are
critical for the metabolism of steroid hormones (AKR1C1–1C3), prostaglandins
(AKR1C3), and PAH trans-dihydrodiols (AKR1C1–1C4).138 These enzymes are highly
homologous and share over 84% sequence identity. AKR1C1 and AKR1C2 are the most
similar and differ by only seven amino acids.
AKR1C enzymes possess 3-keto-, 17-keto- and 20-keto-steroid reductase activity.
AKR1C1 is the predominant 20-ketosteroid reductase in humans and converts
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progesterone to the inactive steroid 20α-hydroxyprogesterone.137 AKR1C2 is a
predominant

3-ketosteroid

reductase

implicated

in

the

metabolism

of

5α-

dihydrotestosterone to produce the inactive androgen 5α-androstan-3α,17β-diol.139 It has
been extensively studied for its role in androgen insufficiency and abnormal prostate
growth.139 AKR1C2 is distinguished from the other 3α-HSDs by its high affinity for bile
acids and may be involved in bile acid transport. AKR1C3 is a type 5 17β-HSD involved
in the formation of potent androgens and estrogens: the reduction of Δ4-androstene-3,17dione

to

testosterone,

the

reduction

of

5α-androstane-3,17-dione

to

5α-

dihydrotestosterone and the reduction of estrone to 17β-estradiol.137, 140-141
Human AKR1C enzymes are implicated in the metabolism of xenobiotics.
AKR1C1 – AKR1C4 are involved in PAH chemical carcinogenesis and activate (-)-R,R
and (+)-S,S stereoisomers of the racemic PAH trans-dihydrodiols into their
corresponding ortho-quinones (o-quinones). o-Quinones may be enzymatic and nonenzymatically reduced back to catechols which can establish futile redox cycles in which
ROS is amplified and cellular reducing equivalents such as NAPDH are depleted.142-143
NQO1, AKRs, and carbonyl reductases are the major enzymes which mediate reduction
of the o-quinone and facilitate redox cycling (Shultz et al., 2011, Penning, 2014).124, 144
An unusual enzymatic function of AKR1C3 was reported during investigation of
PR-104, a prodrug of a nitrogen mustard that has shown mild clinical success in adult
patients with relapsed/refractory acute myeloid leukemia.39,

145

This nitroaromatic

prodrug was designed to be activated under hypoxia, but AKR1C3 activates it to the
DNA cross-linking hydroxylamine and amino metabolites in an oxygen-independent
manner, indicating that it can function as a Type I nitroreductase.38-39 Guise and
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colleagues examined AKR1C1-1C4, AKR1B1, AKR1B10, and NQO1, but only
AKR1C3 displayed nitroreductase activity towards PR-104A.38
1.3.3

Regulation of AKR1C genes
Multiple transcription factors regulate the expression of human AKR genes,

which could have profound impacts on the metabolism of endogenous steroids, prodrugs,
and carcinogens. These enzymes can be considered cytoprotective through their ability to
detoxify reactive aldehydes and ketones, and they are evolutionary conserved across
phyla. AKRs have been identified in archaebacteria, prokaryotes, and eukaroytes.128 The
AKR genes encoding these enzymes can be considered stress response genes because they
are regulated by oxidative, electrophilic, and osmotic stressors, and heat shock.146-149
AKR1C genes are primarily regulated by antioxidant response elements (ARE,
Figure 1.7) which are responsive to Nrf2-Keap1 signaling (see Section 1.4), but nuclear
factor-Y (NF-Y) and AP-1 may play minor roles as well.149 A TESS transcription factor
consensus sequence search revealed 2 – 15 AREs within the promoters of human AKR1C
genes (Table 1.2). Functional AREs have been identified 6.3 kb upstream from the
transcription start site in the AKR1C1 gene, 5.5 kb upstream from AKR1C2, and 1.4 and
6.8 kb upstream of AKR1C3.147, 150 Functionality of these AREs was demonstrated by
RNase protection assays, mutational analysis of the element, transient transfection of
Nrf2 to show increased transcription from reporter gene constructs, and the failure to
observe a response in Nrf2-null cells.147, 150
Ciaccio and Tew initially reported the induction of AKR genes in human
colorectal cancer (HT29) cells by classical Nrf2 activators (dimethyl maleate, t-butyl
hydroquinone (tBHQ), and hydroquinone).151 The human AKR1C genes are among the
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most responsive genes to Nrf2 induction via treatment with Nrf2 activator sulforaphane
(SFN), tBHQ, or siRNA-mediated suppression of the Nrf2 repressor Keap1 in human
HaCaT keratinocytes, MCF10A mammary cells, IMR-32 neuroblastoma cells, and U937
lymphoma cells.152-154 Most studies report a 10-fold to 39-fold increase in transcript
levels due to Nrf2 activation which is equivalent or greater than that of NQO1.152-154
NQO1 is widely used as a biomarker of Nrf2 activation, but recent studies have begun to
incorporate AKR1C1 or AKR1C3 as an indicator of Nrf2 activation.153 Nrf2 signaling is
often constitutively active in many cancers, and so it is unsurprising that increased
expression of AKR1C1-1C3 genes has been detected in prostate cancer, breast cancer,
lung cancer, squamous cell carcinoma of the esophagus, and leukemia.149,

155-157

AKR1C1-1C3 and AKR1B10 are consistently among the highest overexpressed genes in
lung samples from non-small cell lung carcinoma (NSCLC) patients in microarray-based
studies, which has led to their potential application as diagnostic markers of NSCLC.157161

AKR1C1-1C3 have also been characterized as part of the ‘smoking gene battery’

because they are upregulated in bronchial epithelial cells of smokers and are
downregulated in smokers who have quit.162-165 This is likely due to activation of Nrf2
signaling by cigarette smoke.
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Figure 1.7. The antioxidant response element. The ARE consensus sequence reported
in the literature on the basis of mutation analyses of gene reporter plasmids based
primarily on rat, mouse, and human GST and NQO1 genes (A). The positional matrices
for the human ARE sequences, Jasper IDs MA0150.1, which have been generated by the
frequency at which these sites have been found experimentally to be occupied by Nrf2
(B). Adapted from Tebay et al., 2015.
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Table 1.2. ARE consensus sequences in human AKR1C genes
No. of AREs based on
Nrf2 consensus
sequence

Positional matrix
human LD <6

AKR1C1 3(20α)-HSD; DD1

10

16

AKR1C2 Type 3 3α-HSD; DD2

15

24

Type 5 17β-HSD;
AKR1C3 prostaglandin F synthase;
DDX

4

6

AKR1C4 Type 1 3α-HSD; DD4

2

2

Gene
name

Nonsystematic name

Identification of known and putative ARE sequences within human AKR genes was
performed using the Tess PWM search software. The number of AREs were calculated
by searching for the Nrf2 consensus sequence (5′-G-TGAC-NNN-GC-3′) and the
matrices assigned the Jasper IDs MA0150.1 (human Nrf2, NFE2L2). This software
employs a search algorithm of the target gene sequence using a positional/partial weight
matrix to describe the ARE. Adapted from Tebay et al., 2015.
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1.4
1.4.1

Nrf2-KEAP1 signaling

Introduction to Nrf2-Keap1-ARE signaling
The nuclear factor erythroid 2-related factor 2 (Nrf2) is a member of the cap ‘n’

collar (CNC) subfamily of basic region leucine zipper (bZip) transcription factors that
regulates hundreds of genes involved in the cytoprotective response against oxidative
stress. Under basal conditions, Nrf2 binds its negative regulator Kelch-like ECHassociated protein 1 (Keap1) which forms a RING E3-ubiquitin ligase with Cullin3/Rbx1 and rapidly targets Nrf2 for ubiquitination and proteasomal degradation.166-168
Newly transcribed Nrf2 monomers bind Keap1 dimers sequentially via the high-affinity
ETGE motif to form the open confirmation, and then through the low-affinity DLG motif
to form the closed confirmation.169-170 Ubiquitination of Nrf2 only occurs in the closed
configuration.171 Electrophiles and oxidants (termed Nrf2 inducers or activators) modify
specific cysteine residues within Keap1 to prevent ubiquitination of Nrf2.172

As a

consequence, Keap1 is stuck in the closed configuration with Nrf2 and is not regenerated,
and newly synthesized Nrf2 translocates to the nucleus to upregulate genes that contain
ARE sequences within their promoter regions (Figure 1.8).
In the nucleus, Nrf2 heterodimerizes with small musculoaponeurotic fibrosarcoma
protein (sMaf) and binds to AREs to activate transcription of phase II enzymes,
antioxidant synthesis genes, and drug transporters.173-175 Genomic analysis has revealed
that the cis-acting ARE consensus sequence is 5′-(G/A)TGA(G/C)NNNGC(G/A)-3′,
where “N” signifies apparently redundant residues. The ARE consensus sequence was
first identified in the murine glutathione S-transferase (GST) gene and has since been
identified in NQO1, UDP-glucuronosyltransferases (UGT), epoxide hydrolase, and genes
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that encode cellular NADPH regenerating enzymes (glucose 6-phosphate dehydrogenase,
6-phosphogluconate dehydrogenase, and malic enzyme).176 Several Gst genes are
upregulated in mice by Nrf2 signaling, but this is not observed in humans.177-178 Nrf2
upregulation is more frequently associated with the induction of AKR1A1, AKR1B10,
AKR1C1, AKR1C2, and AKR1C3 genes in humans.179 Nrf2 also activates genes involved
in antioxidant synthesis for the two major redox systems, glutathione and thioredoxin. As
a result, several ARE-containing genes mediate detoxification or exert antioxidant
functions which protect cells from oxidative and electrophilic damage.
There has been considerable interest in developing Nrf2 activators as
chemopreventative agents to protect against environmental stressors. Nrf2 activators
include oxidizable diphenols, phenylenediamines, quinones, Michael acceptors,
isothiocyanates, thiocarbamates, dithiolethiones, peroxides, mercaptans, and heavy
metals.180-181 Structure-activity studies have determined that many ARE inducers possess
the chemical property of being able to interact with sulfhydryl groups of Keap1 via
oxidation or alkylation.182 SFN, a major isothiocyanate in broccoli sprouts and mature
broccoli, is one of the most well characterized Nrf2 activators (Figure 1.9).183-184 SFN is
thought to directly interact with Keap1 by covalently binding to its thiol groups.172 The
synthetic

triterpenoid

1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole

(CDDO-Im) has also been extensively characterized as a highly potent Nrf2 activator
with fewer cytotoxic effects compared to SFN or tBHQ.185 Oltipraz has entered clinical
trials for lung chemoprevention and management of chronic liver disease.186
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Figure 1.8. Nrf2-Keap1-ARE signaling. Under basal conditions, Keap1 binds Nrf2 and
facilitates the transfer of ubiquitin for proteasomal degradation. Once Nrf2 is degraded,
Keap1 is free to bind newly synthesized Nrf2 and the cycle continues. Under stressed
conditions, electrophiles modify key cysteine residues on Keap1 which prevents ubiquitin
transfer, so Keap1 remains bound to Nrf2. Newly synthesized Nrf2 evades Keap1 and
translocates to the nucleus to upregulate ARE-genes.
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Figure 1.9. Structure of representative Nrf2 activators.
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1.4.2

Nrf2 Signaling and Chemoprevention
Carcinogenesis is a multistep process involving tumor initiation, promotion, and

progression.187 Initiation results from irreversible genetic damage such as mutations
generated during faulty DNA adduct repair. By contrast, tumor promotion is reversible
and results from altered global gene expression which leads to selective clonal expansion
of initiated cells (benign cells). Progression is the transformation of benign tumors into
malignant

tumors

with

metastatic

properties.188

An

effective

strategy

for

chemoprevention is the reduction of DNA damage by inhibiting the formation of reactive
metabolites from parent carcinogens or stimulating their detoxification.189-190
Nrf2 activators have been designed as chemopreventatives because they
upregulate antioxidant synthesis genes, phase II conjugation enzymes, and drug
transporter enzymes which promote detoxification. Development of Nrf2 activators for
clinical trials has largely been driven by the observation that Nrf2−/− mice are more
sensitive to acute and chronic exposures to several carcinogens.180 Increased levels of
B[a]P-DNA adducts and gastric neoplasia have been observed in the forestomach of
Nrf2-null nice following exposure to B[a]P.191-192 Likewise, B[a]P and DEE exposures
increase DNA adduct formation in lungs of Nrf2−/− mice.193-194 SFN is protective against
carcinogen-induced tumorigenesis in Nrf2+/+ mice models but fails to reduce
tumorigenesis in Nrf2−/− mice.195 SFN has reduced tumor incidence due to numerous
carcinogens (e.g. B[a]P, ultraviolet light, dimthylbenz[a]anthracene, 4-nitroquinoline-1oxide, among others) in the skin, stomach, colon, lung, prostrate, and bladder of murine
models.196 CDDO-Im has been shown to inhibit aflatoxin-induced liver tumorigenesis in
rodents.185
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Clinical trials with Nrf2 activators in humans have been met with mixed success.
In a randomized clinical trial in China (NCT 01437501), a broccoli sprout beverage
enriched in SFN is being tested as a strategy to reduce the incidence of environmental
lung cancer.197

Egner and colleagues reported an increase in benzene and acrolein

mercapturic acid conjugates which indicates an elevated detoxication rate of these
carcinogens.197 It is too early to determine whether consuming a broccoli sprout beverage
had an effect on lung cancer incidence in this study, but consumption of broccoli and
other cruciferous vegetables has been correlated with the reduction of cancer risk in
colon, lung, breast, and prostate in epidemiological studies.198-201 Clinical trials have also
been conducted with oltipraz, a dithiolethione which induces Nrf2 signaling. A
randomized, double-blind trial in smokers with oltipraz failed to detect significant
differences in PAH-DNA adduct levels in lung epithelial cells and blood, indicating that
detoxication of PAHs did not occur.186 Oltipraz significantly increased excreted levels of
aflatoxin-mercapturic acid conjugates in a randomized, double-blind trial in in China
where dietary aflatoxin exposure is high, but no effects were observed on biomarkers of
oxidative stress or genotoxicity.

202-204

Together, these data indicate that Nrf2 induction

may increase excretion of carcinogens via mercapturic acid conjugates, but it is unclear
whether this has a functional impact on DNA adduct levels or biomarkers of oxidative
stress.
1.4.3

The Dark Side of Nrf2: Cancer Promotion
Despite promising data that Nrf2 activators reduce tumorigenesis and DNA

adduct burden in murine models exposed to environmental carcinogens, Nrf2 signaling
has been established as a tumor promoter and is constitutively active in many cancers.
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Elevated Nrf2 signaling due to somatic KEAP1 gene mutations, insertions, and deletions
have been detected in the following cancer types: lung,205-206 pancreas,207 breast,208
gallbladder,209 liver,

209

ovarian,210 endometrial,211 skin,212 and airway.212 In these

cancers, high Nrf2 activity is associated with poor treatment prognosis by causing
resistance to cancer chemotherapeutic agents including cisplatin, doxorubicin, and
etoposide.213-214 Neuroblastoma, breast, and lung carcinoma cell lines are resistant to
chemotherapies in vitro due to Nrf2 induction with tBHQ or stable transfection of Nrf2,
and they could be sensitized to chemotherapy by genetic knockdown of Nrf2.215
Constitutive Nrf2 signaling also disrupts cell cycle progression and increases proliferative
capacity of cell lines in vitro.216 In this context Nrf2 inhibitors are being developed to
counter drug resistance to chemotherapies.217-219
Timing of Nrf2 signaling may dictate its role in cancer. A long-term urethane
(ethyl carbamate)-induced lung carcinogenesis model with wildtype Nrf2+/+ or Nrf2-/mice was employed to explore the role of Nrf2 signaling in initiation and progression of
cancer.220-221 Nrf2−/− mice developed a large number of urethane-induced lung
micronodules in the early phase after urethane administration (4 or 8 weeks) compared to
the wildtype Nrf2+/+ which supports the notion that Nrf2 signaling is chemopreventive.
By 16 weeks, the Nrf2+/+ mice had developed large tumors while the majority of Nrf2−/−
mice had smaller tumors. The most striking observation was made at 24 weeks, where
Nrf2−/− mice possessed significantly smaller and fewer tumors compared with the Nrf2+/+
mice.221 The heterozygous (Nrf2+/−) mice also showed an increased number of lung
surface tumors compared with the Nrf2−/− mice, suggesting that Nrf2 signaling plays an
important role in the long term promotion and progression of urethane-induced lung
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carcinogenesis. These data indicate that Nrf2-targeted chemoprevention strategies need to
be applied with extreme caution.
1.5

Rationale

Nitroreduction in mammalian systems by Type I nitroreductases beyond NQO1 is
poorly understood. When evaluating off-target toxicities of nitroaromatic prodrugs, it was
clearly demonstrated that human liver can activate these compounds to potent DNA
crosslinking agents via nitroreduction, but this could not be attributed to NQO1 or
POR.39, 48 Given the importance of nitroreduction for prodrug activation and chemical
carcinogenesis, other nitroreductase candidates should be explored. AKR1C3 was
recognized as a nitroreductase against the prodrug nitrogen mustard PR-104A, but the
AKRs have yet to be investigated for their ability to toxify nitroaromatic carcinogens,
such as the NO2-PAHs.
NO2-PAHs are highly mutagenic compounds enriched in DEE. DEE is a known
human carcinogen that increases the lung cancer risk in exposed populations. Up to 5 –
7% of the lung cancer incidence burden can be attributed to high levels of DEE and urban
pollution in the United States and Europe.82-83 Given that a small fraction of exposed
individuals go on to develop lung cancer, more work is required to understand the
carcinogenic constituents of DEE and identify determinants of individual susceptibility to
lung cancer. NO2-PAHs are currently classified as possible or probable carcinogens by
the IARC and they require metabolic activation to exert their mutagenic and tumorigenic
effects because it is their electrophilic metabolites that form DNA adducts and promote
mutagenesis. The direct-acting mutagenicity of air particulate samples containing NO2PAHs is two-fold higher than fractions lacking NO2-PAHs.86 NO2-PAHs have been
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detected in excised tumors of non-smokers with lung cancer indicating these compounds
may be related to lung cancer causation.44, 51
Given these data, I aimed to further characterize the metabolic activation of 3-NBA
by human nitroreductases. Inhibition studies have shown that NQO1 is the primary
enzyme that catalyzes the nitroreduction of 3-NBA in rat liver and human hepatocytes,
but this may not be representative of bioactivation of NO2-PAHs.98, 222 Inhalation is the
primary route of exposure to these carcinogens.

AKR1C1-1C3 genes are highly

expressed in human lung tissue and AKR1C3 has previously displayed nitroreductase
activity to nitroaromatic prodrug PR-104A, raising the potential that AKR1C enzymes
may have other nitroaromatic substrates that could be activated within the lung.
Finally, NQO1 and AKR1C genes are highly upregulated by Nrf2 signaling in
humans.152-154 Nrf2 signaling possesses a well-recognized ‘dark side’ in cancer promotion
and progression, but many groups are still investigating its protective role in the context
of cancer initiation. A common hypothesis is that Nrf2 activation prior to initiation is
helpful to protect against chemical insults, but Nrf2 signaling after an initiation event can
drive cancer cell proliferation and enhance progression of tumors.220-221,

223

However,

given the mechanism of 3-NBA toxication, upregulation of ARE genes (NQO1,
AKR1C1-1C3) could exacerbate these exposures and may not facilitate chemoprevention.
All cancer initiation studies with Nrf2 activators have been conducted in rodents, and
many not reflect what occurs in humans. First, key components of the ARE-gene battery
differ in humans: the GST genes are highly activated in mice by Nrf2 induction, but are
not in humans, which could have profound effects on detoxification of xenobiotics.177-178
Second, none of the murine AKR1C genes are orthologs of the human genes, and it is not
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known if the murine AKR1C genes are Nrf2 regulated.224

Therefore, I aimed to

investigate whether Nrf2 signaling affects the bioactivation of 3-NBA in human cell lines
which could indicate that Nrf2 may have an unrecognized role in cancer initiation in
certain exposure contexts.
1.6
1.6.1

Thesis Objectives

The Role of Human Aldo-Keto Reductases in the Metabolic Activation of the
Carcinogenic Air Pollutant 3-Nitrobenzanthrone

AKR1C3 exhibits nitroreductase activity towards the nitroaromatic prodrug PR104A, but its ability to activate NO2-PAHs has not yet been investigated. The first
objective of this thesis was to examine whether human recombinant AKRs exhibited
nitroreductase activity towards 3-NBA which was selected as a representative NO2-PAH.
3-NBA is the most mutagenic compound identified to date in the presence of bacterial
nitroreductases, and thus evaluation of its bioactivation by human enzymes is warranted.
If AKR enzymes displayed nitroreductase activity towards 3-NBA, I planned to measure
the Kcat, Km, and catalytic efficiencies (Kcat/Km) of relevant human recombinant AKRs
and NQO1 to compare the nitroreductase activity of these enzymes. I also developed a
method for detecting 3-NBA metabolites in cell culture in order to assess the individual
contribution of candidate nitroreductases to 3-NBA reduction in human lung bronchial
epithelial cells in vitro.
1.6.2

Nrf2 Knockout by CRISPR-Cas9 Reduces Bioactivation of the Mutagenic
Air Pollutant 3-Nitrobenzanthrone
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AKR1C1-1C3 and NQO1 contain AREs within their promoters and are among the
most induced genes by Nrf2 signaling in humans. Since adenocarcinoma human alveolar
basal epithelial (A549) cells possess constitutively active Nrf2 signaling due to a Keap1
mutation and epigenetic silencing,205 they represent a model system that should allow
maximal 3-NBA toxication. The second objective of this thesis was to assess how Nrf2
knockdown in A549 cells affected AKR1C1-1C3 and NQO1 expression, 3-NBA
bioactivation, and 3-NBA-mediated cytotoxicity.

To modulate Nrf2 signaling and

downstream AKR1C1-1C3 and NQO1 expression, I examined the effect of heterozygous
(Nrf2-Het) and homozygous knockout (Nrf2-KO) of Nrf2 by CRISPR-Cas9 gene editing.
The regulation of AKR1C1-1C3 and NQO1 was compared at the mRNA and protein
level. 3-NBA metabolites were quantified in vitro to determine whether a full or partial
knockdown of Nrf2 signaling decreased the bioactivation of this carcinogen. Given that
Nrf2 signaling is expected to be protective against oxidative stress and DNA damage, I
assessed whether Nrf2 deletion had an effect on cell viability and cytotoxicity in the
context of 3-NBA exposures. Identification of a link between Nrf2 signaling and
bioactivation of 3-NBA would question whether elevated Nrf2 signaling prevents cancer
initiation in the context of 3-NBA exposures.
1.6.3

Nrf2 Induction of the Antioxidant Response Increases Bioactivation of the
Mutagenic Air Pollutant 3-Nitrobenzanthrone in Human Bronchial
Epithelial Cells
Nrf2 activators have entered clinical trials as chemopreventive agents given that

they reduce tumor burden in animal models following exposure to chemical carcinogens
(B[a]P, aflatoxin, 7,12-dimethylbenz(a)anthracene). However, 3-NBA may represent a
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class of environmental carcinogens that are not detoxified by enhanced Nrf2 activity. The
third objective of this thesis was to investigate whether elevated Nrf2 signaling due to
pharmacological inducers enhanced metabolic activation of 3-NBA via upregulation of
NQO1 and AKR1C1-1C3 in immortalized human bronchial epithelial cells. Previous
studies have reported that AKR1C1-1C3 undergo the greatest fold change following Nrf2
induction in immortalized human keratinocytes and human breast epithelial cells.152, 154
However, the effects of Nrf2 activators on AKR1C1-1C3 and NQO1 expression in
immortalized human bronchial epithelial cells have yet to be determined. Given that
Nrf2 signaling is expected to be protective against oxidative stress and DNA damage, I
assessed whether Nrf2 activators had an effect on cell viability and cytotoxicity in the
context of 3-NBA exposures. If Nrf2 activators increased the bioactivation of 3-NBA,
this would question their use as a chemopreventive strategy in the context of diesel
exhaust and air pollution exposures.
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2

THE ROLE OF HUMAN ALDO-KETO REDUCTASES IN THE METABOLIC
ACTIVATION OF THE CARCINOGENIC AIR POLLUTANT
3-NITROBENZANTHRONE

This chapter presents work featured in the article:
Murray, J. R.; Mesaros, C. A.; Arlt, V. M.; Seidel, A.; Blair, I. A.; Penning, T. M., Role
of Human Aldo-Keto Reductases in the Metabolic Activation of the Carcinogenic Air
Pollutant 3-Nitrobenzanthrone. Chemical Research in Toxicology 2018, 31 (11), 12771288.
It has been reformatted here in accordance with the University of Pennsylvania
dissertation guidelines.
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2.1

Introduction

Lung cancer is the leading cause of cancer death worldwide.225 Although lung
cancer is largely attributed to tobacco smoking,226-227 outdoor air pollution represents a
growing threat to public health.228-230 The World Health Organization (WHO) estimated
223,000 lung cancer deaths in 2010 were due to air pollution which has since been
designated as a Group 1 “known human carcinogen” by the International Agency for
Research on Cancer (IARC).52, 228 A major source of air pollution includes diesel engine
exhaust which has also been classified as a Group 1 “known human carcinogen” by
IARC.71 Carcinogens found uniquely in diesel exhaust particulates include the nitrated
polycyclic aromatic hydrocarbons (NO2-PAHs) which may increase the risk of lung
cancer in exposed individuals.77,

79, 82, 231-233

NO2-PAHs are adhered to superfine

particulate matter (PM2.5) in ambient air which can accumulate in the alveolar epithelia
of the deep lung of exposed individuals,74, 234 and they have been detected in lung tissue
of non-smokers with lung cancer.51, 232
However, not all individuals exposed to diesel exhaust develop lung cancer,
indicating that gene-environment interactions may be important in determining individual
risk for developing this disease.85,

235

NO2-PAHs require metabolic activation to exert

their mutagenic and tumorigenic effects,236 and identification of human enzymes that can
metabolically activate these carcinogens will provide insight into identifying genetic
variants and transcriptomic changes that may determine individual susceptibility. I chose
to further characterize the metabolic activation of 3-nitrobenzanthrone (3-nitro-7Hbenz[de]anthracen-7-one, 3-NBA)44 since it is the most mutagenic compound identified
in the Ames test to date,109,

237

and it is a potent mutagen and lung carcinogen in
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rodents.108, 118, 238-240 Metabolic activation of 3-NBA involves a 6-electron reduction of
the nitro-group involving sequential formation of the nitroso, hydroxylamino, and amine
products catalyzed by cytosolic nitroreductases (Figure 2.1).241-243 The hydroxylamino
intermediate, N-hydroxy-3-aminobenzanthrone (N-OH-3-ABA) is intercepted by
sulfonation or acetylation, creating a good leaving group for attack of the intermediate
nitrenium or carbenium ion to DNA bases resulting in the formation of DNA adducts. 99,
107, 244-246

Its final product, 3-aminobenzanthrone (3-ABA, Figure 2.1) can also be

activated by peroxidases to yield either a nitrenium or carbenium ion that can contribute
to DNA adduct formation.97, 100 3-NBA exposure leads to DNA adduct formation in vitro
and in multiple organs in vivo in rodents112, 244, 247-249 and in human cells.114, 234, 250-252 3ABA has been found in the urine of salt-mine workers occupationally exposed to diesel
exhaust which indicates human exposure to 3-NBA and their ability to metabolize it.110
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Figure 2.1 Proposed pathways of metabolic activation of 3-NBA and resulting DNA
adduct formation. We propose that AKR enzymes may contribute to the nitroreduction
of 3-NBA. Abbreviations used: NQO1, NAD(P)H:quinone oxidoreductase 1; NAT1/2,
N,O-acetyltransferase isozymes; SULT1A1/1A2, sulfotransferases 1A1 and 1A2; P450,
cytochrome P450; MPO, myeloperoxidase. Modified from Arlt et al., 2006.
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Identification of genes involved in the metabolic activation of representative NO2PAHs, such as 3-NBA, will be necessary to identify genotypes of sensitive individuals or
predict phenotypic changes that may sensitize individuals to diesel exhaust exposures. 3NBA has previously been shown to be metabolically activated by xanthine oxidase (XO),
NADPH:cytochrome

P450

oxidoreductase

(POR),

and

oxidoreductase 1 (NQO1) to yield N-OH-3-ABA or 3-ABA.99,

NAD(P)H:quinone
104, 222, 253

Inhibition

studies have shown that NQO1 is the primary enzyme that catalyzes the nitroreduction of
3-NBA in liver in vitro.98, 102, 222
Since human aldo-keto reductase 1C3 (AKR1C3) displays greater nitroreductase
activity than NQO1 towards the activation of the cancer chemotherapeutic agent PR104A, I sought to characterize whether AKRs could contribute to the nitroreduction of 3NBA in humans.38 The ability of AKR1Cs to display nitroreductase activity against PR104A was unexpected since these enzymes typically conduct a two electron reduction on
carbonyl groups.254 AKR1C1-1C3 are highly expressed in human lung tissue which is
relevant as inhalation is the primary route of exposure to NO2-PAHs.51,

148, 255

I

demonstrate here that human AKR1C1-1C3 are able to catalyze the nitroreduction of 3NBA and therefore may be involved in toxification of NO2-PAHs.
2.2
2.2.1

Results

Activation of 3-nitrobenzanthrone by human aldo-keto reductases
Previous work by Guise et al. reported that AKR1C3 displayed nitroreductase

activity towards the chemotherapeutic agent PR-104A.38 To determine whether human
AKR1C enzymes could display nitroreductase activity towards nitrated polycyclic
aromatic hydrocarbons (NO2-PAHs), I investigated whether AKR1C1-1C4 would be able
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to metabolically activate 3-NBA. Discontinuous enzymatic assays were initially
performed with 1.68 μM enzyme (AKR1C1-1C4) and 8.2 μM 3-NBA in potassium
phosphate buffer pH 7 at 37 °C in a 2 mL system to screen for nitroreductase activity. In
order to characterize the reaction over time, 100 μL aliquots were sampled at 15 min, 30
min, 45 min and at 1, 3, 6, 9, 18, and 24 h. An NADPH-regeneration system consisting of
glucose-6-phosphate (G6P) and glucose-6-phoshate dehydrogenase (G6PD) was
necessary to drive the reaction to completion within 24 hours. The disappearance of 3NBA and formation of the six-electron reduction product, 3-ABA, was monitored with
reverse phase HPLC coupled to in–line photo–diode–array (PDA) detection.
Under these conditions, 3-ABA appeared within 15 minutes after initiation with
AKR1C1-1C3 and continued to increase in a time-dependent manner (Figure 2.2). 3ABA formation was quantified by integrating the peak that appeared at 27.2 minutes in
the UV-chromatograms (Figure 2.2, A). The observed 3-ABA formation was due to
enzyme activity as less than 2% of 3-NBA was converted to 3-ABA in control reactions
that lacked enzyme. Human recombinant AKR1A1, AKR1B1, AKR1B10, AKR1D1,
AKR7A2, and AKR7A3 were tested and were found to not contribute to the
nitroreduction of 3-NBA (Supplemental Data, Figure S2-1). Human AKR1C1-1C3
enzymes were the most efficient. AKR1C4 possessed less than 10% of the nitroreductase
activity towards 3-NBA compared to AKR1C1-1C3 and was not further characterized.
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Figure 2.2. AKR1C3 catalyzes the nitroreduction of 3-NBA. 3-ABA was identified in
discontinuous assays with AKR1C3 using UV-HPLC monitoring at 279 nm (A). 3-NBA
and 3-ABA were identified based on retention times and UV spectra which were
compared to standards. 3-NBA and 3-ABA levels were quantified over a 24 h time course
(B). Results were similar for AKR1C1, AKR1C2, and NQO1.
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UV-HPLC detection of 3-NBA and 3-ABA allowed us to determine that AKR1C
enzymes displayed nitroreductase activity, but the nitroso and hydroxylamino
intermediates were not identified in the UV-HPLC chromatograms. Evidence for the
formation of the nitroso and hydroxylamino intermediates and 3-ABA were instead
obtained using UPLC-HRMS/MS. These analytes gave exact mass within 5 ppm for the
parent ion and the corresponding fragment ions in the MS2 spectrum.
The two-electron reduction product, 3-NOBA, was identified in enzymatic
reactions that contained AKR1C1-1C3 and NQO1 at 3 h with m/z of 260.0708 and an
elution time of 21.6 min (Figure 2.3). Its fragment ion corresponding to the loss of the
carbonyl (MH+-CO m/z = 232.0757) and loss of the nitroso group (MH+-NO m/z =
230.0729) were detected within ± 5 ppm. The hydroxylamino intermediate N-OH-3-ABA
(MH+ m/z = 262.0855) was also identified in reactions with AKR1C1-1C3 and NQO1 at
3 h. It was identified in the pseudo-SRM chromatograms and eluted at 27.8-27.9 min
with m/z of 262.0867 (Figure 2.4). Its fragments corresponded to the loss of the hydroxyl
(MH+-OH m/z = 245.0895) and carbonyl (MH+-CO m/z = 234.0814) that were detected
within the given parameters (± 5 ppm).
Both the nitroso and hydroxylamino intermediates were unstable, and were
subsequently detected in low amounts, with intensities of 1.07E6 and 6.28E5,
respectively. Much higher levels of the product 3-ABA were detected with an intensity of
1.80E6 in the peak eluting at 18.03 min with m/z of 246.0916 (Figure 2.5). 3-ABA was
not detected by HRMS/MS in any enzymatic reactions at the 0 h time point. Small
amounts of both intermediates were detected at the 0 h time point however, indicating
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either minimal contamination of 3-NBA or rapid conversion of 3-NBA to these
intermediates prior to organic extraction.
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Figure 2.3. UPLC-HRMS/MS detection of 3-NOBA. Aliquots of enzymatic reactions
with AKR1C1-1C3 and NQO1 were sampled at 0 h (left panels A, C) and 3 h (right
panels B, D). Data are shown for the reaction with AKR1C3 but are representative of
each enzymatic reaction. 3-NOBA MH+ was detected at m/z = 260.0706, and two
fragments were identified: MH+-CO m/z = 232.0757 and MH+-NO m/z = 230.0729. 3NOBA and its fragments were detected within 5 ppm of their predicted m/z.
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Figure 2.4. UPLC-HRMS/MS detection of N-OH-3-ABA. Aliquots of enzymatic
reactions with AKR1C1-1C3 and NQO1 were sampled at 0 h (left panels A, C) and 3 h
(right panels B, D). Data are shown for the reaction with AKR1C3 but are representative
of each enzymatic reaction. N-OH-3-ABA MH+ was detected at m/z = 262.0855, and two
fragments were identified: MH+-OH m/z = 245.0814 and MH+-CO m/z = 234.0895. NOH-3-ABA and its fragments were detected within 5 ppm of their predicted m/z.
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Figure 2.5. UPLC-HRMS/MS detection of 3-ABA. Aliquots of enzymatic reactions
with AKR1C1-1C3 and NQO1 were sampled at 0 h (left panels A, C) and 3 h (right
panels B, D). Data are shown for the reaction with AKR1C3 but are representative of
each enzymatic reaction. 3-ABA MH+ was detected at m/z = 246.0919, and two
fragments were identified: MH+-NH2 m/z = 230.0729 and MH+-CO m/z = 218.0957. 3ABA and its fragments were detected within 5 ppm of their predicted m/z.
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2.2.2

Comparison of AKR1C1-1C3 to NQO1
Since NQO1 had been previously identified as the major nitroreductase in the

metabolic activation of 3-NBA in vitro, I calculated Km, kcat, and catalytic efficiencies
(kcat/Km) of AKR1C1-1C3 and NQO1 to compare these enzymes for their ability to
reduce 3-NBA and form 3-ABA. These assays were optimized so that the amount of
enzyme used was in the linear range for each protein as determined by plots of initial
velocity versus enzyme concentrations. Discontinuous enzymatic assays with AKR1Cs
were performed in 50 mM potassium phosphate buffer pH 7 at 37 °C in a 1 mL system
using 0.5 µM AKR1C1-1C3 with 0 – 30 µM 3-NBA to construct v vs. [S] curves. To
capture the initial velocity during the first 5 – 10% of the reaction, multiple aliquots were
taken in the first 30 min. The formation of the six-electron reduction product, 3-ABA,
was monitored with reverse phase HPLC coupled to in–line PDA detection at 279 nm.
Discontinuous enzymatic assays with NQO1 were performed as described above with
0.25 µM NQO1. Initial velocity (v) vs. [S] curves were fit with the Michaelis-Menten
equation using GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA) to calculate Km
and kcat, and kcat/Km (Figure 2.6). kcat/Km values were termed “apparent catalytic
efficiencies” since substrate concentrations were not significantly lower than Km values
due to the detection limits of this assay.
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Figure 2.6. v vs. [S] curves for AKR1C1-1C3 and NQO1. Discontinuous enzymatic
assays were performed in 50 mM potassium phosphate buffer pH 7 at 37 °C in a 1 mL
system using 0.5 µM AKR1C1-1C3 or 0.25 µM NQO1 with 0 – 30 µM 3-NBA to
construct v vs. [S] curves. Initial velocity (v) vs. [S] curves were fit with the MichaelisMenten equation using GraphPad Prism 7.0 to calculate Vmax, Km, and kcat.
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I found that AKR1C1, AKR1C3, and NQO1 had very similar apparent catalytic
efficiencies (~8 min-1 mM-1 vs. ~7 min-1 mM-1) despite the much higher kcat of NQO1
(0.058 min-1 vs. 0.012 min-1). AKR1C1-1C3 possessed a much lower Km than NQO1:
AKR1C1 and AKR1C3 had Km values 1.43 – 1.5 µM while the Km for NQO1 was 8.8
µM. AKR1C2 had a similar Km when compared to AKR1C1 and AKR1C3 but had a
lower kcat, and thus its apparent catalytic efficiency was 50% less than AKR1C1 and
AKR1C3. AKR1C4 was a very poor nitroreductase for 3-NBA and so it was difficult to
obtain steady state kinetic parameters for AKR1C4. AKR1C4 is a liver-specific AKR1C
isozyme and I expect that it will not contribute to 3-ABA formation in the lung.

Table 2.1. Catalytic efficiencies for 3-NBA turnover by NQO1 and AKR1C11C3
Recombinant
Km
kcat
kcat/Km
-1
Enzyme
(µM)
(min )
(min-1 mM-1)
NQO1

8.8 ± 2.5

0.058 ± 0.0066

6.59

AKR1C1

1.5 ± 0.27

0.012 ± 0.0004

8.00

AKR1C2
AKR1C3

1.1 ± 0.29
1.4 ± 0.43

0.004 ± 0.0002
0.012 ± 0.0007

3.63
8.39

2.2.3

Relative contributions of AKR1C1-1C3 and NQO1 in vitro
Apparent catalytic efficiencies suggest that AKR1C1-1C3 may compete with

NQO1 and contribute to the nitroreduction of 3-NBA. To determine the relative
contributions of these enzymes in human lung epithelial cells, I modified a 96-well plate
assay to monitor the formation of 3-ABA in A549 cells.256 First I established that human
lung cells metabolically activate 3-NBA in submerged cell culture. A549 cells exposed to
five different concentrations of 3-NBA ranging from 0.625 – 10 M revealed time- and
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dose-dependent formation of 3-ABA measured by an increase of cellular fluorescence
intensity compared to non-exposed cells. Elevated fluorescence was observed by 60 min
following exposure to 0.625 – 10 M 3-NBA and increased throughout the 48 h time
course (Figure 2.7, A).
HBEC3-KTs also metabolically activate 3-NBA and form 3-ABA in a time- and
dose-dependent manner. Due to the lower metabolic activity of this cell line and reduced
sensitivity of 3-ABA detection in HBEC3-KT media (K-SFM), the time to first detect an
increase in fluorescence was 6 h, but this was below the linear range of 3-ABA detection
(Figure 2.7, B). Reliable measurements for formation of 3-ABA after exposure to 0.625
– 10 µM 3-NBA concentrations could be obtained after 24 h and continued to increase
over 48 h.
To assess the contribution of NQO1 vs AKR1C1-1C3 in each cell line, I
monitored the formation of 3-ABA in the presence and absence of dicoumarol (a NQO1
inhibitor) and flufenamic acid (a pan-AKR1C inhibitor). Together, these enzymes
account for approximately 50% of the nitroreduction of 3-NBA, and AKR1C enzymes
make a significant contribution that is similar to that of NQO1 in both cell lines (Figure
2.8). Flufenamic acid reduced total 3-ABA formation by 34 ± 5% in A549 and 33 ± 7%
in HBEC3-KT while dicoumarol reduced total 3-ABA formation by 23 ± 6% in A549
and 40 ± 6% in HBEC3-KT. The combination treatment (10 µM dicoumarol + 50 µM
flufenamic acid, abbreviated DF) led to 45 ± 8% reduction of 3-ABA formation in A549
and 53 ± 8% in HBEC3-KT.
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Figure 2.7. 3-ABA formation in A549 and HBEC3-KT cells. Determination of the
metabolic activation of 3-NBA to 3-ABA in A549 (A) and HBEC3-KT (B) cells. The
intrinsic fluorescence of 3-ABA (λex 520 nm, λem 650 nm) was used to detect the final
reduction product, 3-ABA. Fluorescence was monitored over a timespan from 1 h to 48 h
in A549 (n=3) and 1 h to 48 h in HBEC3-KT (n=5). Elevated fluorescence levels were
observed at 0.625 µM by 1 h in A549 cells and by 6 h in HBEC3-KT.
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Figure 2.8.

Inhibition of 3-ABA formation by AKR1C and NQO1 inhibitors.

Specific inhibitors were used to assess individual contributions of AKR1C1-1C3, NQO1,
XO, and complex 1 in catalyzing nitroreduction of 3-NBA in A549 (A) and HBEC3-KT
(B) cell lines exposed to 2.5 µM 3-NBA. Abbreviations used: Dic, Dicoumarol; FA,
Flufenamic Acid; DF, combination treatment with Dicoumarol and Flufenamic Acid; SA,
Salicylic Acid; Urso, Ursodeoxycholate; Indo, Indomethacin; Allo, Allopurinol; and Rot,
Rotenone. Experiments were repeated at least 5 independent times (n = 5-7).
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To further assess the role of individual AKR1C enzymes, salicylic acid was
selected as a specific inhibitor against AKR1C1 (IC50: 5.8 µM), ursodeoxycholate is a
specific inhibitor against AKR1C2 (IC50: 236 nM), and indomethacin is a specific
inhibitor against AKR1C3 (IC50: 108 nM). Several concentrations between 0 – 100 µM
were tested for each inhibitor to determine the lowest concentration in which they
produced maximal inhibition of 3-ABA formation. Salicylic acid inhibited 3-ABA
formation by approximately 18% in A549 cells and 4% in HBEC3-KT, ursodeoxycholate
inhibited 3-ABA formation by approximately 33% in A549 cells and 5% in HBEC3-KT,
and indomethacin inhibited 3-ABA formation by approximately 5% in A549 cells and
19% in HBEC3-KT.
Allopurinol (XO inhibitor) was included in the inhibitor screen as XO has been
previously implicated in the reduction of 3-NBA.97 XO plays a minor role in the
metabolic activation of 3-NBA and contributes approximately 9-11% of 3-ABA
formation in A549 and HBEC3-KT cell lines. Rotenone was included to rule out
contribution of mitochondrial nitroreductases as it is a Complex I inhibitor. Rotenone
inhibits approximately 12% of total 3-ABA formation in A549 and HBEC3-KT cells, but
with high variability. It is likely that mitochondrial nitroreductases play a minor role in
the formation of 3-ABA.
2.3

Discussion

3-NBA is a potent mutagen and suspected human carcinogen present in diesel
engine exhaust and ambient air particulate matter which requires metabolic activation in
order to promote its mutagenic and tumorigenic effects.71, 77, 79, 82, 109, 111, 231-233 Previous
research has suggested that NQO1 is the major nitroreductase responsible for 3-NBA
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activation, but this work has largely been conducted in human hepatic cytosols98 and
primary human hepatocytes104 which may not be reflective of 3-NBA bioactivation
following inhalation exposures. To further characterize the metabolic activation of 3NBA, I examined the role of human AKR enzymes due to reports that AKR1C3
nitroreductase activity superseded that of NQO1 towards the cancer therapeutic PR104A.38 AKR1C genes are also among the most upregulated genes in non-small cell lung
cancer and in bronchial epithelial cells exposed to environmental carcinogens.38, 158, 162-165
I established the ability of AKR1C1-1C3 to act as nitroreductases via detection of
the final reduction product 3-ABA in discontinuous enzymatic assays using HPLC-UV
chromatography, and a product-precursor relationship was established. I found evidence
for the formation of the nitroso and hydroxylamino intermediates via UPLC-HRMS, but
these intermediates were not produced in significant quantities which suggests that these
intermediates are unstable or are quickly metabolized to 3-ABA, the final reduction
product. The ability of AKR1C enzymes to catalyze the reduction of 3-NBA and
sequentially generate the nitroso and hydroxylamino intermediates is unusual since the
AKRs conduct a single 2-electron reduction of carbonyl groups followed by the ordered
release of reduced product and NADP+.125 This is the first time to our knowledge that
AKR1C enzymes have been implicated in the metabolic activation of NO2-PAHs by
acting as nitroreductases.
The present study examined AKR1C1-1C3 and NQO1 in cell-free systems to
compare their kinetic constants (Km, kcat, kcat/Km). I found that the apparent catalytic
efficiencies (kcat/Km) for 3-ABA formation were nearly equivalent for AKR1C1,
AKR1C3, and NQO1. Other AKR1C isozymes have variable nitroreductase activity
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towards 3-NBA: AKR1C2 had a lower kcat/Km than AKR1C1 and AKR1C3 while liverspecific AKR1C4 had negligible nitroreductase activity.

kcat/Km is best applied to

measure catalytic efficiency when the substrate concentrations cover the range 0.2 – 5.0
Km, but this was not achieved due our limitations in detecting 3-ABA in the low substrate
range. Our lower limit of detection of 3-ABA was 0.005 nmol, which required higher
substrate concentrations (1 – 30 µM) in the reaction system to form sufficient quantities
of 3-ABA within the period that 3-ABA formation was linear with time. Despite these
limitations, these apparent catalytic efficiencies are a useful comparator of the abilities of
AKR1C1-1C3 and NQO1 to reduce 3-NBA. Although NQO1 has a higher turnover
number, AKR1Cs possess much lower Km values than NQO1. The low Km observed with
AKR1C enzymes suggests that that they may be more important than NQO1 at the low
concentrations of 3-NBA to which humans are exposed by inhalation.
I chose to evaluate the relative importance of AKR1C1-1C3 and NQO1 in human
lung epithelial cell lines as the respiratory tract is the primary site of exposure to 3-NBA.
3-NBA-induced DNA adduct formation (i.e. 3-NBA activation) has also been observed in
cultured human A549252,

257-258

, TT1234 and BEAS-2B259-260 lung cell lines. Our data

suggest that the combined activities of AKR1C1-1C3 and NQO1 contribute equally in the
reduction of 3-NBA in A549 and HBEC3-KT cell lines. Flufenamic acid, a pan-AKR1C
inhibitor, and dicoumarol, a NQO1 inhibitor, reduced 3-ABA formation in cell culture to
a similar extent in both cell lines. Although the contribution of NQO1 to the total
nitroreductase activity is greater than any single AKR1C enzyme, the combined activities
of AKR1C1-1C3 are roughly equivalent to NQO1 in these lung cell lines. However, the
contribution of individual AKR1C isozymes may differ between cell lines. The use of
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specific inhibitors against individual AKR1C enzymes (salicylic acid, ursodeoxycholate,
and indomethacin) suggests that AKR1C2 contributes to a much greater percentage of 3NBA reduction than AKR1C1 and AKR1C3 in A549 cells while AKR1C3 appears to be
the dominant isozyme in HBEC3-KT cells. This may be due to variability in relative
expression of AKR1C1-1C3 between cell lines.
A549 cells displayed greater nitroreductase activity towards 3-NBA than HBEC3KT cells which is to be expected since A549 cells have higher levels of AKR1C1-1C3
and NQO1 due to constitutively active nuclear factor (erythroid-derived 2)-like 2
(Nrf2).261-262 AKR1C and NQO1 genes are induced by the Nrf2-Keap1 pathway and
possess antioxidant response elements (ARE) in their promoters. AKR1C1-AKR1C3
genes contain multiple AREs (6-16 based on a positional matrix search) in their
promoters and are among the most highly induced genes by the Nrf2-Keap1 system in
humans yet the least studied.125, 150-151, 154, 263 NQO1 is a prototypic Nrf2-regulated gene
which is induced by exposures to NO2-PAHs, and so it is thought that NO2-PAHs may
induce their own genotoxicity by increasing transcription of NQO1.102-103, 264 A similar
phenomena is observed in the metabolic activation of PAHs by AKRs as their reactive
metabolites (PAH ortho-quinones, ROS) upregulate Nrf2 and further upregulate AKR1C
genes, thus enhancing PAH bioactivation and genotoxicity.147, 151 AKR1C genes are also
part of the “smoking gene battery” – genes that are upregulated in bronchial epithelial
cells of smokers and are downregulated in smokers who have quit.162-165 Interestingly,
Nrf-targeted chemopreventatives such as R-sulforaphane (R-SFN) induce AKR1C and
NQO1 genes.151 Given the similarities in the induction of AKR1C1-1C3 and NQO1, both
gene families will likely be over-expressed during exposures to NO2-PAHs which will
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exacerbate metabolic activation of these compounds. This raises the question about the
safety of indiscriminate use of Nrf2-targeted chemoprevention therapies as there may be
certain environmental exposures that are toxified by Nrf2 activity.
Our data from this study suggest that monitoring expression of both NQO1 and
AKR1C1-1C3 may provide insight into ability of cells and tissues to bioactivate 3-NBA.
Human AKR1C isozymes have been previously implicated in the metabolic activation of
PAHs via their dihydrodiol dehydrogenase activity to produce electrophilic and redoxactive ortho-quinones (o-quinones).265-269 However, our work suggests for the first time
that they may also be important for the metabolic activation of NO2-PAHs via
nitroreductase activity.
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2.4

Supplemental Data

Figure S2-1. Human recombinant AKRs screened for nitroreductase activity against
3-NBA. 3-ABA was quantified in discontinuous assays with AKR enzymes using UVHPLC monitoring at 279 nm to estimate the percentage of 3-NBA reduction. Control
reactions contained all reaction components except enzyme (3-NBA and NAPDH
regeneration system).
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3

NRF2 KNOCKOUT BY CRISPR-CAS9 REDUCES BIOACTIVATION OF THE
MUTAGENIC AIR POLLUTANT 3-NITROBENZANTHRONE

This chapter presents work featured in the article:
Murray, J. R.; de la Vega, L.; Hayes, J.D.; Duan, L.; Penning, T. M. Nrf2 Induction of
the Antioxidant Response Increases Bioactivation of the Mutagenic Air Pollutant 3Nitrobenzanthrone in Human Lung Cells. In preparation.
It has been reformatted here in accordance with the University of Pennsylvania
dissertation guidelines.
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3.1

Introduction

Identification of genes involved in the metabolic activation of representative NO2PAHs, such as 3-NBA, will be necessary to identify susceptible groups that may carry
genetic variants or epigenetic modification of those genes. I have previously
demonstrated that aldo-keto reductase 1C1, 1C2, and 1C3 (AKR1C1-1C3) display
nitroreductase activity towards 3-NBA. This was the first time that AKR1C1 and 1C2
were recognized as nitroreductases and the second recorded observation that AKR1C3
can exhibit reductase activity towards nitroaromatic compounds in an oxygenindependent manner.38, 124, 270 AKRs are primarily recognized as ketosteroid reductases
and/or hydroxysteroid dehydrogenases, so these findings were surprising. In both of these
cases, AKR1C family members could compete with the widely recognized nitroreductase
NADPH:Quinone Oxidoreductase 1 (NQO1). I found that catalytic efficiencies of NQO1,
AKR1C1, and AKR1C3 are equivalent for the reduction of 3-NBA and that these
enzymes contribute equally in the reduction of 3-NBA in human bronchial epithelial cells
in vitro.270 Notably, both AKR1C1-1C3 and NQO1 contain antioxidant response element
(ARE) sequences within their promoters and are among the most upregulated genes by
Nrf2 signaling in humans.
Nrf2 is a master regulator of stress response genes and its activation increases the
antioxidant capacity of the cell under stressed conditions.179,

271-272

Under basal

conditions Nrf2 is recruited to Keap1 which rapidly targets Nrf2 for ubiquitination and
proteasomal degradation.166 Under stressed conditions, electrophiles and reactive oxygen
species modify key cysteine residues in Keap1 which prevents ubiquitination of Nrf2.169,
273-274

Newly synthesized Nrf2 can thus evade ubiquitination, translocate to the nucleus
69

and bind to its heterodimeric partner small-Maf on ARE sequences of stress responsive
genes.170, 175, 271 Remarkably, AKR1C1-AKR1C3 genes are induced 4.8–39-fold in human
cell lines following activation of Nrf2, whereas NQO1 is only induced 1.2–4.8-fold.152, 154
The adenocarcinoma human alveolar basal epithelial (A549) cell line was
employed in this study because Nrf2 is constitutively active (i.e. derepressed) which
results in high levels of expression of AKR1C1-1C3 and NQO1.215, 262 This is due to an
inactivating mutation in Keap1 which prevents it from binding to Nrf2 and epigentic
silencing of Keap1 gene via hypermethylation of its promoter.205

I was able to

manipulate expression of NQO1 and AKR1C1-1C3 in A549 cells with heterozygous and
homozygous genetic knockout of the endogenous NFE2L2 gene, which encodes Nrf2,
via CRISPR-Cas9 to determine the effect of dysregulation of Nrf2 signaling on the
toxication of 3-NBA. Since these cells lack functional Keap1 protein, they should be
resistant to regulation of Nrf2 signaling by environmental stimuli and represent a model
system to investigate high, intermediate, and absent levels of Nrf2 signaling.
3.2
3.2.1

Results

Manipulating Nrf2 Signaling in A549 Cells
To investigate the role of Nrf2-Keap1 signaling on 3-NBA activation, I first

examined the basal expression of ARE-regulated genes in A549 cells by qPCR (Figure
3.1). A549 cells are expected to maintain high expression levels of ARE-genes due to
constitutive activation of Nrf2.215,

262

As a result, ‘wildtype’ A549 cells which express

maximal Nrf2 activity were anticipated to be relatively unresponsive to Nrf2 activators
such as SFN and CDDO-Im. To manipulate Nrf2 signaling in A549 cells, genetic
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knockout was required; A549 cells with homozygous knockout (A549 Nrf2-KO) and
heterozygous knockout (A549 Nrf2-Het) of the endogenous NFE2L2 gene were utilized
for this study. When these three cell lines (A549 Nrf2-KO, A549 Nrf2-Het, and A549 wt)
were assayed by western blot, I observed complete knockout of Nrf2 in the nuclear
fraction in the Nrf2-KO cells and a partial knockdown in the Nrf2-Het cells (Figure 3.2).
I also verified that Nrf2 activators did not increase Nrf2 localization to the nucleus or
increase transcription of AKR1C and NQO1 genes in A549 Nrf2-KO, A549 Nrf2-Het,
and A549 wt cell lines (Supplementary Figure S1-S2).
To further understand the effect of homozygous and heterozygous Nrf2 knockout
on ARE regulated genes, I quantified transcript and protein levels of AKR1C1-1C3 and
NQO1. I found that Nrf2 signaling is required for basal expression of AKR1C1-1C3 as
these mRNA transcripts and proteins were essentially absent from the A549 Nrf2-KO
cells. By contrast, NQO1 experienced a decrease of 60-68% in Nrf2-KO cells, relative to
the A549 wt control. NQO1 mRNA and protein levels seemed unaffected in Nrf2-Het
cells but were reduced in the Nrf2-KO cells.
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Figure 1. Heterozygous and homozygous knockdown of Nrf2 in A549 cells have
differential effects on AKR1C1-1C3 and NQO1 expression. Gene expression of
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AKR1C1-1C3 and NQO1 were quantified in three cell line variants of A549 (A549 wt,
A549 Nrf2-Het, and A549 Nrf2-KO) and expressed as copy number normalized to
GAPDH. Bar graphs show mean copy number ± SD of n = 3/group for AKR1C1 (A),
AKR1C2 (B), AKR1C3 (C), and NQO1 (D). Absolute expression levels of each gene
were analyzed by one-way ANOVA with a post-hoc Dunnett’s multiple comparison test
to assess the difference in gene expression due to Nrf2 signaling across cell lines.
Asterisks indicate a statistically significant difference from the A549 wt cell line (*p ≤
0.05; *** p ≤ 0.001; **** p ≤ 0.0001).
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Figure 3.2. Heterozygous and homozygous knockdown of Nrf2 in A549 cells have
differential effects on AKR1C1-1C3 and NQO1 protein levels. Protein samples from
cell line variants of A549 (A549 wt, A549 Nrf2-Het, and A549 Nrf2-KO) were collected
in three independent experiments and were quantified by immunoblot analysis (A). Band
intensities of cytosolic proteins were normalized to α-Tubulin and band intensities of
nuclear protein were normalized to Lamin A. Bar graphs show mean normalized
intensities ± SD of n = 3/group (B). The AKR1C1 and AKR1C2 family members were
collectively referred to as AKR1C1/2 because immunoblot techniques were not able to
differentiate between them. A NQO1 activity assay was conducted in the three A549 cell
lines (C). Bar graphs show mean ± SD of n = 3/group. Reduction of Nrf2, AKR1C1-1C3,
and NQO1 protein levels or enzyme activity due to Nrf2 knockout were statistically
significant when tested by a one-way ANOVA with a post-hoc Dunnett’s multiple
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comparison test (*p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001). wt A549 cells
were used as a reference for statistical analysis for each protein.
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The absolute mRNA level of each gene was expressed as copy number
normalized to GAPDH which revealed that AKR1C1, AKR1C2, and AKR1C3 were
expressed at similar levels in A549 wt cells (Figure 3.1). These three isoforms
experienced different sensitivities to Nrf2 knockout. AKR1C1 transcript levels
experienced a 57% reduction in the heterozygous knockout and a 99.5% reduction in the
homozygous Nrf2 knockout cell line. These changes were statistically significant.
AKR1C2 transcript levels were virtually unchanged (0.3% decrease) in the heterozygous
knockout and reduced by 98.7% in the homozygous Nrf2 knockout. Finally, AKR1C3
transcript levels experienced a 20% reduction in the heterozygous knockout and a 92.4%
reduction in the homozygous Nrf2 knockout. Only changes in the homozygous knockout
were statistically significant for AKR1C2-1C3. These results were confirmed at the
protein level. AKR1C1 and AKR1C2 (Swiss Prot: Q04828/P52895) protein sequences
are 98% identical and the antibody used (ab179448) recognizes both isoforms (labeled
AKR1C1/2). The band corresponding to AKR1C1/2 was essentially undetectable in
Nrf2-KO cells (Figure 3.2). The abundance of AKR1C1/2 protein was also reduced in
Nrf2-Het cells compared to the A549 Nrf2-wt cells. It is impossible to determine whether
both isoforms are present or their relative protein levels based on this antibody, but I
would expect that AKR1C1 protein levels are reduced to a greater extent than AKR1C2
based on qPCR results. Protein levels of AKR1C3 were visualized using a specific
antibody and were in accordance with qPCR results.
NQO1 was not as sensitive to the Nrf2 heterozygous or homozygous knockout
compared to AKR1C1-1C3 (Figure 3.1). No reduction was observed in the heterozygous
knockout while a 68.3% reduction of NQO1 transcript levels was observed in the
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homozygous Nrf2 knockout. These results were mirrored in the western blot as NQO1
protein levels were reduced but detectable in the Nrf2-KO cells, and no significant
difference was observed between the A549 Nrf2-Het and A549 wt cell lines (Figure 3.2).
I conducted Prochaska assays to measure NQO1 enzyme activity as a readout of
Nrf2 signaling.275 Enzyme activity measurements differed slightly from immunoblot
results, and I found a 29% reduction of NQO1 activity in Nrf2-Het cells compared to
A549 wt cells which suggests that the partial Nrf2 knockout leads to slightly reduced
NQO1 activity levels. I also observed a 70% reduction of NQO1 activity in the Nrf2-KO
cell lines compared to A549 wt cells, indicating a dose-response relationship between
Nrf2 signaling and NQO1 activity where each functional copy of Nrf2 contributes to
approximately 30% of NQO1 enzyme activity (Figure 3.2 C).
3.2.2

Effect of Nrf2 Knockdown on 3-NBA Toxication
Given that heterozygous and homozygous knockout of Nrf2 drastically reduced

mRNA and protein levels of AKR1C1-1C3 and NQO1, I used a 96-well plate assay to
monitor 3-ABA formation in vitro with low and high doses of 3-NBA (1.25 µM and 10
µM 3-NBA, respectively). Maximal differences in 3-ABA formation across cell line were
observed by 8 h following treatment. Cells were lysed following 3-ABA measurements
for protein quantification with a BCA Assay Kit (Pierce Biotechnology, Rockford, IL).
Protein normalization was necessary given the differences in cell proliferation between
each cell line due to Nrf2 knockout (Figure 3.3). This has been observed previously, and
I accounted for these differences with protein normalization.276-277 BCA results also
confirmed that average protein levels of A549 Nrf2-KO cells were approximately 35%
lower than that of A549 wt cells 24 h after plating 1 x 104 cells (data not shown).
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Figure 3.3. Effects of Nrf2 on proliferation of A549 cell lines. To monitor proliferation
of A549 wt, A549 Nrf2-Het, and A549 Nrf2-KO cell lines, 1 x 103 cells were plated per
well and monitored over a 96 h time course (A). Images are representative of four
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independent experiments (n=4). Cell counts were then normalized to area and expressed
as number of cells per mm2 (B). Plotted time course shows mean cell counts ± SD
of n = 4/cell line.
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Heterozygous Nrf2 knockout led to 53% ± 8.2% and 52% ± 15.7% decreases in
total 3-ABA formation in A549 Nrf2-Het cells following exposure to a low dose (1.25
µM) and high dose (10 µM) of 3-NBA, respectively (Figure 3.4). Meanwhile,
homozygous Nrf2 knockout led to 80% ± 5.5% and 78% ± 9.0% decreases in total 3ABA formation in A549 Nrf2-KO cells following exposure to a low dose (1.25 µM) and
high dose (10 µM) of 3-NBA, respectively. The effect of reduced Nrf2 signaling is
consistent regardless of the 3-NBA dose received (tested four doses between 1.25-10 µM
3-NBA, data not shown). It is likely that basal levels of NQO1 activity contribute to 3ABA formation in the Nrf2-KO cell line because 29% of total NQO1 activity remained in
this cell line despite complete loss of Nrf2 and AKR1C1-1C3 protein levels (Figure 3.2).
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Figure 3.4. Reduction in Nrf2 signaling leads to decreased formation of 3-ABA in a
dose-dependent manner. Determination of the metabolic activation of 3-NBA to 3-ABA
in A549 cell variants (A549 wt, A549 Nrf2-Het, and A549 Nrf2-KO). The intrinsic
fluorescence of 3-ABA (λex 520 nm, λem 650 nm) was used to detect the final reduction
product 3-ABA after 8 h of exposure to 1.25 or 10 µM 3-NBA. Values are expressed as
mean ± SD and data were analyzed by a two-way ANOVA with a post-hoc Dunnett’s
multiple comparison test to assess the difference in 3-ABA formation due to Nrf2
signaling within each 3-NBA treatment group. Asterisks indicate a statistically significant
difference from the A549 wt cell line (** p ≤ 0.01; **** p ≤ 0.0001). wt A549 cells were
used as a reference for statistical analysis. Experiments were repeated four independent
times (n = 4).
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3.2.3

Effect of Nrf2 Knockdown on 3-NBA Cytotoxicity
Given that Nrf2 signaling increases the antioxidant capacity of the cell and plays a

critical role in the cellular defense against oxidative and electrophilic stressors, I
examined the effect of Nrf2 signaling on cell viability and death following 3-NBA
exposure. I assessed cell viability following a 24 h exposure period to 3-NBA under the
same conditions described above for the 3-ABA formation assays. A549 cells were
seeded at 1 x 104 per well in 96-well plates and were exposed to low and high doses of 3NBA (1.25 µM and 10 µM, respectively) after a 24 h attachment period. I found that cell
viability was unaffected in A549 Nrf2-Het cells following exposure to both 1.25 and 10
µM 3-NBA, indicating that one copy of Nrf2 was sufficient to protect against
electrophilic and oxidative stress mediated by this carcinogen. However, I found that cell
viability was significantly reduced by 40% in A549 Nrf2-KO following exposure to 10
µM 3-NBA (Figure 3.5, A). There were no significant changes in viability in A549 Nrf2KO cells treated with 1.25 µM 3-NBA relative to A549 wt cells treated with vehicle
control.
Cell death was also measured to assess cytotoxicity. A549 cells were plated as
described above and were exposed to low and high doses of 3-NBA (1.25 µM and 10
µM, respectively). After a 24 h exposure period to 3-NBA, cells were stained with
Hoechst and Sytox Green to estimate total and dead cell counts. The only significant
finding observed was an increase in cell death after exposure to 10 µM 3-NBA in the
Nrf2-KO cells, which is in agreement with cell viability studies. No significant increases
in cell death were observed within A549 wt or Nrf2-Het cell lines (Figure 3.5, B-C).
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Figure 3.5. The effect of Nrf2 signaling on cell viability and cytotoxicity in A549
cells. MTT-based cell viability was assayed using A549 cell variants (A549 wt, A549
Nrf2-Het, and A549 Nrf2-KO) exposed to 1.25 µM and 10 µM 3-NBA (A). Bar graphs
show mean ± SD from three independent experiments. To measure cytotoxicity, A549
wt, Nrf2-Het and Nrf2-KO cells were treated with 1.25 µM and 10 µM 3-NBA and
stained with Sytox Green and Hoechst at 24 h (B-C). Cell death was expressed as a
percentage of the total cell count. Bar graphs show mean ± SD of n = 3/group. Data were
analyzed by a two-way ANOVA with a post-hoc Dunnett’s multiple comparison test to
assess the difference in viability or cell death within each 3-NBA treatment group due to
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Nrf2 knockout status. Asterisks indicate a statistically significant difference from the
vehicle treatment (0.1% DMSO) in A549 wt cells (*** p ≤ 0.001; **** p ≤ 0.001).

84

3.3

Discussion

Among all the human genes regulated by the Nrf2-Keap pathway, AKR1C1-1C3
and NQO1 are consistently the most overexpressed in response to Nrf2 inducers (or
activators).153-154 The metabolic activation of 3-NBA requires nitroreduction and is
performed by these enzymes in human lung cells where 34% of 3-NBA nitroreduction is
attributed to AKR1Cs and up to 40% is attributed to NQO1.270 In this study I sought to
determine the role of Nrf2 knockout on 3-NBA toxication in vitro as measured by 3-ABA
formation, cell viability, and cell death in human cells.
I first quantified the expression of AKR1C1-1C3 and NQO1 in A549 cells that
possessed heterozygous or homozygous knockout of Nrf2. I found that AKR1C1-1C3
were most sensitive to Nrf2 knockdown and that Nrf2 signaling was essential for their
transcription. Both mRNA and protein levels were almost nonexistent for AKR1C1-1C3
in the A549 Nrf2-KO cell line. By contrast 30% of NQO1 transcript levels and enzyme
activity remained in the absence of Nrf2 suggesting that other transcription factors
control its constitutive expression, such as AP-1 or AP-2.278 This observation differs
from nrf2−/− mouse embryonic fibroblasts which lack measurable Nqo1 protein or mRNA
levels, suggesting that the murine models may not accurately predict Nrf2 regulation of
NQO1 in humans.279
I found decreases of 52 – 53% and 72 – 80% in 3-NBA activation due to
heterozygous and homozygous Nrf2 knockout, respectively. I also observed that
constitutive expression of Nrf2 increased the growth of A549 cells demonstrating its
oncogenic and proliferative potential.280-281 This difference in growth rate was
compensated by normalizing 3-ABA formation to protein. Given that knockdown of Nrf2
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signaling reduced 3-ABA formation, it is possible that elevated Nrf2 signaling due to
pharmacological activators may also increase 3-NBA bioactivation. This finding is
intriguing given that Nrf2 activators have been used as chemopreventive agents in the
context of environmental air pollution.197
Homozygous KO of Nrf2 was deleterious in the context of high exposures to 3NBA, and I observed decreased viability and increased cell death following exposure to
10 µM 3-NBA. This is expected given that the Nrf2-Keap1 axis plays a pivotal role in
regulating the redox status of cells. However, it was surprising that no differences in
viability and cell death were observed between A549 Nrf2-wt and Nrf2-Het cells
following exposure to 3-NBA. This finding is significant because it indicates that
constitutively elevated Nrf2 activity in ‘wildtype’ A549 cells did not offer any more
protection from 3-NBA compared to intermediate levels of Nrf2 in the heterozygous
knockout. This questions whether elevated Nrf2 signaling via pharmacological activators
will promote cell survival and reduce cytotoxicity in the context of 3-NBA exposures.

86

3.4

Supplemental Data

Figure S3-1. Nrf2 activators (CDDO-Im and SFN) did not alter AKR1C1-1C3 or
NQO1 transcription. Gene expression was measured by qPCR in A549 wt (A), A549
Nrf2-Het cells (B), or A549 Nrf2-KO (C) cells. Treatment with 1.25 µM 3-NBA also
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failed to significantly change AKR1C1-1C3 or NQO1 transcript levels, indicating that
A549 cells with CRISPR-Cas9 knockout of Nrf2 possess stable expression of ARE-genes
that were not further induced through Nrf2-dependent or independent mechanisms during
exposures to 3-NBA. Bar graphs show mean ± SD of n = 2/group. The effect of Nrf2
treatment on the expression levels of each gene was analyzed by a one-way ANOVA
with a post-hoc Dunnett’s multiple comparison test.
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Figure S3-2. Nrf2 activators (CDDO-Im and SFN) did not affect Nrf2 signaling.
Activators failed to recruit Nrf2 to the nucleus and did not alter AKR1C1-1C3 or NQO1
protein levels in A549 cell line variants (A). Western blot is representative of three
independent experiments. Treatment with 1.25 µM 3-NBA also failed to significantly
change AKR1C1-1C3 or NQO1 protein levels (B), indicating that A549 cells with
CRISPR-Cas9 knockout of Nrf2 possessed stable protein expression of ARE-genes that

89

are not further induced through Nrf2-dependent or independent mechanisms during
exposures to 3-NBA.
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4

INDUCTION OF THE ANTIOXIDANT RESPONSE BY TRANSCRIPTION
FACTOR NRF2 INCREASES BIOACTIVATION OF THE MUTAGENIC AIR
POLLUTANT 3-NITROBENZANTHRONE IN HUMAN LUNG CELLS

This chapter presents work featured in the article:
Murray, J. R.; de la Vega, L.; Hayes, J.D.; Duan, L.; Penning, T. M. Nrf2 Induction of
the Antioxidant Response Increases Bioactivation of the Mutagenic Air Pollutant 3Nitrobenzanthrone in Human Lung Cells. In preparation.
It has been reformatted here in accordance with the University of Pennsylvania
dissertation formatting guidelines.
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4.1

Introduction

Nrf2 is a master regulator of stress response genes and its activation increases the
antioxidant capacity of the cell under stressed conditions.179, 271-272 Nrf2-Keap1 signaling
also plays a pivotal role in manipulating expression of mammalian nitroreductases
(AKR1C1-1C3 and NQO1) which can have major implications for the metabolic
activation of 3-NBA, a potent mutagen and possible human carcinogen. I previously
observed a 53% reduction and a 82% reduction in 3-NBA reduction due to a
heterozygous and homozygous Nrf2 knockout in A549 cells, respectively. This is likely
due to downregulation of AKR1C1-1C3 and NQO1 which collectively account for at least
50% of the nitroreductase activity towards 3-NBA in human lung cells.270 A549 cells
with heterozygous and homozygous Nrf2 knockout present an excellent opportunity to
investigate the effects of Nrf2 signaling on 3-NBA bioactivation because levels of Nrf2
signaling are stable in each cell line due to an inactivating mutation in Keap1. However,
this model relies on transformed adenocarcinoma cell lines which may not accurately
predict the effects of pharmacological induction of Nrf2 in human cells with wildtype
Keap1. The focus of this chapter is to determine if Nrf2 activators could promote 3-NBA
bioactivation in HBEC3-KT cells.
Nrf2 activators such as the isothiocyanate sulforaphane (SFN) and synthetic
triterpenoids

such

as

1[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole

(CDDO-Im), are currently in development as chemopreventive agents given their ability
to induce genes for phase II detoxifying enzymes.282-283 However, if a subset of the
ARE-gene battery contributes to metabolic activation of NO2-PAHs in humans, Nrf2
activation may exacerbate their toxication. The majority of the work with Nrf2 activators
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has been conducted in murine models which may not accurately predict ARE-gene
induction in humans. Recently, the effects of SFN and Keap1 knockout have been
evaluated in a small number of human cell lines, including human breast cells (MCF10A
and MCF12A)154, human keratinocytes (HaCaT),152 and renal epithelial cells (HK-2).153
These studies identified that AKR1B10 and AKR1C1-1C3 were excellent biomarkers of
Nrf2 activity in humans and experienced the greatest magnitude of induction. In many of
these studies, gene expression of AKR1Cs or NQO1 was evaluated with microarrays or
qPCR without protein validation, so it is unknown whether upregulation of AKR1Cs and
NQO1 at the mRNA level will have functional impacts on enzyme activity and 3-NBA
metabolism. Given that inhalation represents the primary route of exposure to 3-NBA and
other NO2-PAHs, I aimed to characterize AKR1C and NQO1 induction in immortalized
human bronchial epithelial (HBEC3-KT) cells. To our knowledge, this is the first time
that the effects of Nrf2 activators have been determined in HBEC3-KT cells which are
considered the best model for normal human bronchial epithelial cells.284
This chapter provides full characterization of two Nrf2 activators in immortalized
HBEC3-KT cells at the mRNA, protein, and enzyme activity levels and investigated their
effects on 3-NBA bioactivation and cytotoxicity. If pharmacological activators of Nrf2
increase toxication of 3-NBA in HBEC3-KT cells, it would question whether such agents
are safe for human use in the context of environmental exposures enriched in NO2-PAHs
(e.g. occupational diesel exhaust, urban air pollution).
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4.2
4.2.1

Results

Manipulating ARE-gene Expression by Nrf2 Activators in HBEC3-KT Cells
I characterized two widely studied activators of Nrf2, namely SFN and CDDO-

Im, for their ability to induce AKR1C and NQO1 at the mRNA and protein level in
immortalized HBEC3-KT cells. Previous studies have reported that AKR1C1-1C3 are
subject to greater fold changes (4.8 – 39-fold increases) following Nrf2 activation than
NQO1 (1.2 – 4.8-fold increases) in immortalized human keratinocytes and human breast
epithelial cells.152,

154

However, the effects of Nrf2 activators in immortalized human

bronchial epithelial cells have yet to be determined.
I first conducted time courses to optimize treatment conditions for HBEC3-KT
cells and Nrf2 activators. I tested AKR1C1 and NQO1 transcript levels at various time
points up to 48 h following treatment with intermediate concentrations of each activator:
10 µM SFN, 50 nM CDDO-Im (data not shown). Maximal induction of our chosen AREdriven genes was observed after 16 h of incubation with both activators. Dose-response
curves were constructed with 7 concentrations of each activator: 1 – 100 µM SFN and 5 –
5000 nM CDDO-Im, using 0.1% DMSO as a vehicle control. A bell-shaped doseresponse curve was observed with SFN suggesting that this agent is cytotoxic and a
bimodal distribution was observed with CDDO-Im. I show results from 2 – 10 µM SFN
and 5 – 50 nM CDDO-Im treatments because the greatest changes in gene transcription
were observed at 10 µM SFN and 50 nM CDDO-Im (Figure 4.1).
These data show that AKR1C1 was the most inducible gene upon Nrf2 activation
at both the absolute levels (copy number normalized to GAPDH) and relative levels
(normalized to vehicle control, 0.1% DMSO) in HBEC3-KT. The changes in gene
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expression were statistically significant across all treatment groups (2-10 µM SFN and 550 nM CDDO-Im). AKR1C1 was subject to a 16.2-fold increase with 10 µM SFN and a
13.5-fold increase with 50 nM CDDO-Im (Figure 4.1 A, C). AKR1C2 also was subject to
high fold-increases with Nrf2 iactivators, 11.1-fold and 2.2-fold increases were observed
with 10 µM SFN and 50 nM CDDO-Im, respectively (Figure 4.1 A, C).

Despite

AKR1C3 being highly responsive to Nrf2 activators in other human cell lines (up to 27fold increase), AKR1C3 transcripts were only induced 2.2-fold following treatement with
10 µM SFN and 2.9-fold following treatment with 50 nM CDDO-Im in HBEC3-KT
cells.152, 154

95

Figure 4.1. Effect of Nrf2 activators on AKR1C1-1C3 and NQO1 expression in
HBEC3-KT cells. HBEC3-KT cells were exposed to multiple doses of SFN treatment (2
– 10 µM) and CDDO-Im (5 – 50 nM) for 16 h. Quantitative RT-PCR was utilized to
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quantify mRNA levels of AKR1C1-1C3 (A, C) and NQO1 (B, D) expressed as copy
number (A, B) or fold-change relative to the non-induced cells that were treated with
vehicle control, 0.1% DMSO (C,D). Expression levels of ARE-genes were normalized to
human GAPDH. Bar graphs show mean ± SD of three independent experiments. To
assess the effect of Nrf2 activators on the absolute expression level of each gene, an oneway ANOVA with a post-hoc Dunnett’s multiple comparison test was performed.
Symbols indicate a statistically significant difference in gene expression from cells
treated with 0.1% DMSO as vehicle control (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; ****
p ≤ 0.0001).
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By contrast NQO1 expression was less sensitive to Nrf2 activators compared to
AKR1C1-1C3. The mRNA for NQO1 showed approx. 4.9-fold and 6.5-fold increases
with SFN and CDDO-Im, respectively (Figure 4.1 D). These increases were statistically
significant. Interestingly, basal and induced levels of NQO1 were much lower than
AKR1C1. Copy number of NQO1 was approximately only 50% of that of AKR1C1 under
non-induced conditions and only 10% following 10 µM SFN treatment.
I next measured AKR1C1 – AKR1C3 and NQO1 protein expression and NQO1
enzyme activity in HBEC3-KT cells following treatment with SFN and CDDO-Im to
validate changes in gene expression at the functional level. For immunoblot analysis,
HBEC3-KT cells were treated with doses of Nrf2 activators which corresponded to
maximal changes in transcript level (10 µM SFN, 50 nM CDDO-Im). Time courses (0 –
48 h) were conducted which determined that maximal levels of AKR1C1-1C3 and NQO1
proteins were achieved 24 h after treatment with SFN or CDDO-Im and remained stable
until 48 h (data not shown). Both 10 µM SFN and 50 nM CDDO-Im led to upregulation
of Nrf2 within the nucleus, as expected (Figure 4.2). Consistent with the mRNA
induction studies, the immunoblot shows that both activators increased AKR1C1/2,
AKR1C3, and NQO1 protein levels in the cytosol. AKR1C1/2 levels were 2.5-fold and
2.6-fold higher following treatment with 10 µM SFN and 50 nM CDDO-Im, respectively;
AKR1C3 levels were 2.2-fold and 1.8-fold higher from 10 µM SFN and 50 nM CDDOIm treatment; and NQO1 levels were 2.3-fold and 2.2-fold higher from 10 µM SFN and
50 nM CDDO-Im treatment. Changes in AKR1C1/2 and AKR1C3 were statistically
significant while NQO1 was not, but this is likely due to high variability in densitometry
measurements.

NQO1 enzyme activity measurements were in accordance with the
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immunoblot results and I found that 10 µM SFN and 50 nM CDDO-Im led to a 2.1-fold
and 2.2-fold increase in NQO1 activity, respectively (Figure 4.2). This is much lower
than the 4.9- to 6.45-fold increases observed at the qPCR level.
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Figure 4.2. Protein levels of AKR1C1-1C3 and NQO1 are increased due to Nrf2
activators. HBEC3-KT cells were exposed to multiple doses of SFN treatment (2 – 10
µM) and CDDO-Im (5 – 50 nM) for 16 h. Quantitative RT-PCR was utilized to quantify
mRNA levels of AKR1C1-1C3 (A - C) and NQO1 (D) expressed as copy number
normalized to human GAPDH. Bar graphs show mean copy number ± SD of three
independent experiments. To assess the effect of Nrf2 activators on the absolute
expression level of each gene, a one-way ANOVA with a post-hoc Dunnett’s multiple
comparison test was performed. Symbols indicate a statistically significant difference in
gene expression from cells treated with 0.1% DMSO as vehicle control (* p ≤ 0.05; **
p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001).
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4.2.2

Effect of Nrf2 Activators on 3-NBA Toxication
After optimizing the induction of AKR1C1-1C3 and NQO1 following Nrf2

activator treatment, I monitored 3-ABA formation in vitro with low and high doses of 3NBA (1.25 µM and 10 µM 3-NBA, respectively). Experiments were conducted under the
same conditions as the Prochaska assay since they were optimized to produce greatest
enzyme activity. Maximal changes in 3-ABA formation were observed by 16 h following
treatment with 5 µM SFN and 50 nM CDDO-Im and were normalized to protein.
Treatment with 3-NBA was unlikely to cause significant upregulation of AKR1C1-1C3
and NQO1 during this period through Nrf2-dependent mechanisms (Supplemental
Figures S4-1).
Following 48 h induction with 5 µM SFN, 3-ABA formation was increased by
44% (± 10.1%) and 40% (± 14.5%) following exposure to a low dose (1.25 µM) and high
dose (10 µM) of 3-NBA, respectively (Figure 4.3). Meanwhile, induction with 50 nM
CDDO-Im led to 60% (± 19.0%) and 42% (± 15.1%) increases in total 3-ABA formation
following exposure to a low dose (1.25 µM) and high dose (10 µM) of 3-NBA,
respectively. Increases in 3-ABA formation were consistent across multiple doses of 3NBA (tested four doses between 1.25 – 10 µM 3-NBA, data not shown); these changes
were statistically significant (p <0.001 or p<0.0001).
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Figure 4.3. Nrf2 activators increased formation of 3-ABA in HBEC3-KT cells.
Determination of the metabolic activation of 3-NBA to 3-ABA in HBEC3-KT due to 5
µM SFN and 50 nM CDDO-Im. The intrinsic fluorescence of 3-ABA (λex 520 nm, λem
650 nm) was used to detect the final reduction product, 3-ABA following 16 h of
exposure to 1.25 or 10 µM 3-NBA. Values are expressed as mean ± SD and data were
analyzed by a two-way ANOVA with a post-hoc Dunnett’s multiple comparison test to
assess the difference in 3-ABA formation due to Nrf2 induction within each 3-NBA
treatment group. Asterisks indicate a statistically significant difference from cells treated
with 0.1% DMSO as vehicle control during the 48 h induction period (** p ≤ 0.01; ***
p ≤ 0.001; **** p ≤ 0.0001). Experiments were repeated 4 independent times (n = 4).
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The formation of 3-ABA reported as pmol µg-1 protein levels are not directly
comparable between the A549 and HBEC3-KT cell lines (Section 3.2.2, Figure 3.4). The
A549 data were collected at an earlier time point so that measured fluorescence was
linear with time and within the range of the calibration curve constructed with an
authentic 3-ABA standard. By contrast HBEC3-KT cells were plated at a much greater
density and required more time to attach to the plates. When data were normalized as
pmol 3-ABA formed per hour per cell number, A549 wt cells formed 48-57% more 3ABA than HBEC3-KT cells treated with vehicle control (Figure 4.4). Cell numbers were
obtained from duplicate plates since the 3-ABA formation assay required solid black
plates.
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Figure 4.4. Determination of the metabolic activation of 3-NBA to 3-ABA in A549
cell variants and HBEC3-KT cells ± Nrf2 activators. The intrinsic fluorescence of 3ABA (λex 520 nm, λem 650 nm) was used to detect the final reduction product 3-ABA.
Formation of 3-ABA was normalized to cell count from duplicate plates that underwent
identical treatment conditions. Values are expressed as mean ± SD and show the relative
formation of fmol 3-ABA per hour per cell. A549 wt cells are able to metabolize 3-NBA
to a much greater extent than HBEC3-KT which is likely due to constitutive Nrf2 activity
and subsequent upregulation of AKR1C1-1C3 and NQO1. Experiments were repeated 4
independent times (n = 4).
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4.2.3

Effect of Nrf2 Activators on 3-NBA Cytotoxicity
Given that 3-NBA metabolites are electrophilic and can redox-cycle to generate

oxidative stress, I wanted to examine whether increased Nrf2 signaling had an effect on
HBEC3-KT cell viability during 3-NBA exposures. Cell viability was assessed by the
reduction of MTT under the same conditions as described for the 3-ABA formation
assay. I observed that pre-treatments with 5 µM SFN or 50 nM CDDO-Im had no effect
in the context of 3-NBA exposures (Figure 4.5, A); there was no statistically significant
difference between cell viability due to Nrf2 induction in the context of exposure to 3NBA. Cytotoxicity experiments were also conducted under the same conditions described
above by staining cells with Sytox Green and Hoechst after 24 h exposure to 1.25 µM
and 10 µM of 3-NBA. Percentage of cell death was compared across treatments in the
presence and absence of Nrf2 induction by SFN and CDDO-Im. Exposure to 1.25 µM
and 10 µM of 3-NBA increased cell death compared to vehicle control (0.1% DMSO),
but no significant differences in cell death were observed in HBEC3-KT due to Nrf2
activator treatment within each 3-NBA exposure group (Figure 4.5, B-C).
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Figure 4.5. Nrf2 induction did not have expected cytoprotective effects for 3-NBA
exposures in HBEC3-KT cells. MTT-based cell viability was assessed in HBEC3-KT
cells that underwent a 48 h exposure to Nrf2 activators or vehicle control prior to
exposure to 1.25 µM and 10 µM 3-NBA (A). Bar graphs show mean ± SD from three
independent experiments. To measure cytotoxicity, HBEC3-KT cells underwent a 48 h
exposure to Nrf2 activators or vehicle control and then were treated with 1.25 µM and 10
µM 3-NBA for 24h. Cells were stained with Sytox Green and Hoechst at 24 h (B-C). Cell
death was expressed as a percentage (# dead cells/# total cells x 100%). Bar graphs show
mean ± SD of n = 3/group (B). Data were analyzed by a two-way ANOVA with a post-
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hoc Dunnett’s multiple comparison test to assess the difference in viability or cell death
within each 3-NBA treatment group due to Nrf2 activator treatment. I did not observe
statistically significant differences from the vehicle treatment (0.1% DMSO).
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4.3

Discussion

I have investigated the basal and induced expression of AKR1C1-1C3 and NQO1
at the mRNA, protein, and enzyme activity level in HBEC3-KT cells. This work
characterizes the possible effect of Nrf2 activators (SFN, CDDO-Im) in human lung
epithelial cells. I found that 10 µM SFN and 50 nM CDDO-Im led to the greatest
changes in AKR1C1-1C3 and NQO1 transcription. Interestingly, AKR1C1 expression
gave the largest response to Nrf2 induction (16.1-fold increase and 13.5-fold increase for
10 µM SFN and 50 nM CDDO-Im, respectively). AKR1C2 expression revealed a greater
sensitivity to induction via SFN rather than CDDO-Im and underwent a 11.1-fold and
2.2-fold increase due to treatment with 10 µM SFN and 50 nM CDDO-Im, respectively.
AKR1C3 fold changes were quite modest by comparison (2.2-fold increase and 2.8-fold
increase for 10 µM SFN and 50 nM CDDO-Im, respectively). By contrast NQO1
transcripts increased by 4.9-fold and 6.5-fold due to 10 µM SFN and 50 nM CDDO-Im.
Functional increases in protein level ranged from 1.8-fold to 2.6-fold for AKR1C1-1C3
and 2.2-fold for NQO1. It is well appreciated that mRNA transcript levels do not always
accurately predict protein levels,285-286 but these changes in protein were sufficient to
increase total 3-NBA bioactivation.
These results differ from what has been observed in other cell lines, indicating
that it may be wise to characterize the effects of Nrf2 activators in multiple target tissues
to understand ARE-gene induction in the region of interest. These changes may impact
carcinogen metabolism in a cell-specific manner. For example, AKR1C3 was upregulated
by 27-fold in a human breast epithelial cell line (MCF10A) treated with SFN and by 3.1fold increase in transformed keratinocytes (human HaCaT).152, 154 Upregulation of NQO1
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is more consistent across cell lines but still displays variability: a 4.4-fold induction was
reported due to SFN in MCF10A cells and 2.52-fold induction in HaCaT cells.
Increased Nrf2 signaling via SFN or CDDO-Im treatment led to significant
increases in 3-NBA toxication (40 – 60% increase in total 3-ABA formation). This is
likely due to 2-fold increases in AKR1C1-1C3 and NQO1 protein levels which
collectively account for at least 50% of the total nitroreductase activity towards 3-NBA in
HBEC3-KT cells. Other unidentified nitroreductases participate in the reduction of 3NBA and may be regulated through Nrf2-dependent and independent mechanisms.
Although increased bioactivation of 3-NBA is expected to increase the stable DNA
adduct burden and enhance mutagenesis, I predicted that activators of Nrf2-target genes
would decrease cytotoxicity in HBEC3-KT cells exposed to 3-NBA given that 3-NBA
promotes oxidative stress.257, 287 Such activators have been previously shown to
ameliorate losses in viability due to oxidative stress.288 However, Nrf2 activators did not
change cell viability or cytotoxicity following exposure to 3-NBA. This suggests that
basal levels of Nrf2 were sufficient to protect against cytotoxic effects of 3-NBA in
human bronchial epithelial cells, or that 3-NBA did not generate sufficient levels of
oxidative stress to perturb HBEC3-KT cells. A similar phenomenon was observed in
A549 cells with a partial CRISPR-Cas9 knockout of Nrf2. No difference was observed in
cytotoxicity measurements between ‘wildtype’ A549 cells that possessed maximal Nrf2
signaling and the heterozygous Nrf2 knockout, suggesting that intermediate levels of
Nrf2 are sufficient to protect against oxidative stress.
Treatment with Nrf2 activators increased 3-ABA formation in HBEC3-KT cells
to a much lower extent than was in A549 cells harboring knockout of Nrf2 (40 – 60%
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increase due to activators in HBEC3-KT vs. 80% decrease due to homozygous knockout
in A549 cells, Figure 4.4). There may be a number of explanations for this difference.
First, the relatively high basal levels of AKR1C1/2, AKR1C3, and NQO1 observed in
HBEC3-KT cells prior to treatment with Nrf2 activators could be in part responsible. It is
clear that low levels of Nrf2 present in HBEC3-KT are sufficient to maintain protein
levels of AKR1C1-1C3 and NQO1. Second, it is possible that 3-NBA exposure could
increase Nrf2 signaling and ARE-gene expression within a 16 h period to induce its own
metabolism. This has been previously reported in rat lung and liver after exposing
animals to 40 mg kg-1 3-NBA.102-103 To address this issue, I examined the effect of 3NBA on induction of ARE-driven genes and did not observe appreciable differences in
AKR1C1-1C3 mRNA and protein levels if HBEC3-KT cells were pre-treated with 3NBA; only modest induction of NQO1 mRNA levels were observed after 24 h treatment
with 3-NBA but this did not affect NQO1 enzyme activity levels (Supplementary
Figure S4-1). Third, 3-ABA formation was used as a readout of total 3-NBA metabolism
in this study, but multiple metabolites promote DNA adduct formation. The
hydroxylamino intermediate, N-hydroxy-3-aminobenzanthrone (N-OH-3-ABA) can be
intercepted by sulfonation or acetylation, creating a good leaving group to form the
intermediate nitrenium or carbenium ion which binds DNA.99, 107, 244-245 3-ABA can also
be oxidized back to N-OH-3-ABA or can be directly activated by peroxidases to yield
either a nitrenium or carbenium ion which contributes to DNA adduct formation.100 Thus
end-point measurements of 3-ABA formation may provide an underestimate of 3-NBA
activation driven by Nrf2 signaling and a future direction would be to measure the 3-
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NBA-derived DNA adduct levels in both A549 cell variants and in HBEC3-KT cells
treated with activators.
These data are in disagreement with the majority of data in the field which
suggests that Nrf2 activation may reduce cancer incidence and tumor burden while Nrf2
knockout can increase cancer incidence. Lungs of Nrf2 knockout mice show reduced
DNA adducts from benzo[a]pyrene and diesel exhaust exposure.193-194

SFN, an

isothiocyanate enriched in broccoli sprouts, has been successfully used to protect against
chemical-induced carcinogenesis in multiple organs in mice.195-196 However, these data
are difficult to evaluate in the context of 3-NBA metabolism in humans because none of
the murine AKR1C genes are orthologs of the human genes and, despite numerous
microarray analyses of Nrf2-target genes having been reported, clear evidence that Nrf2
regulates Akr1c family members in the mouse does not exist.224 Other key components
of the ARE-gene battery are regulated differently in humans when compared to murine
models: glutathione S-transferases (GSTs) are highly upregulated in mice, but are not
upregulated by Nrf2 induction in humans which could have profound effects on
detoxication of xenobiotics.152, 178
In a randomized clinical trial in China (NCT 01437501), a broccoli sprout
beverage (enriched in R-SFN) is being tested to cause a sustained detoxication of
airborne pollutants as a chemopreventive strategy to reduce the incidence of
environmental lung cancer.197 This study is promising because it revealed an increase in
benzene and acrolein mercapturic acid conjugates in the treated group which would be
consistent with the upregulation of glutathione synthesis genes and enhanced detoxication
of these airborne carcinogens. However, this trial did not measure biomarkers of diesel
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exhaust exposure and effect, such as 1-aminopyrene-Hb adducts or NO2-PAH-derived
DNA adducts.289
More work is required to quantify DNA adducts in humans following exposure to
Nrf2 activators and NO2-PAHs. If increases in 3-ABA formation due to treatment with
inducers of Nrf2-target genes lead to an increase in DNA adduct burden and subsequent
G to T transversions, this would indicate Nrf2 activation may be deleterious in preventing
cancer initiation for certain carcinogen exposures. High Nrf2 activity in tumors has been
associated

with

poor

treatment

prognosis

by

causing

resistance

to

cancer

chemotherapeutic agents.213-214 In this context Nrf2 inhibitors are being developed to
counter drug resistance to chemotherapies.217-218
Our work highlights the potential for Nrf2 activation to have deleterious
consequences with respect to cancer initiation: Nrf2 upregulates the antioxidant capacity
of the cell and be protective against compounds that require Phase II conjugation for
detoxication, but it may also drive toxication of a subset of carcinogens that are not
detoxified by Phase II conjugation enzymes. 3-NBA metabolites do not form glutathione
conjugates, rather they undergo sulfonation or acetylation which promotes DNA adduct
formation.107 It is possible that increased rates of 3-NBA bioactivation will correspond to
an increased stable DNA adduct burden in immortalized human bronchial epithelial cells.
This raises questions about the safety of indiscriminate use of Nrf2-targeted
chemoprevention therapies as there may be environmental exposures that are toxified by
elevated Nrf2 activity.
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4.4

Supplemental Data
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Figure S4-1. Nrf2 induction due to 3-NBA is limited. HBEC3-KT cells were exposed
to multiple doses of 3-NBA (0.5 – 10 µM) for 16 h (A). Quantitative RT-PCR was
utilized to quantify mRNA levels of AKR1C1-1C3 and NQO1 expressed as copy number
and normalized to cells that were treated with vehicle control, 0.1% DMSO. Bar graphs
show mean fold change ± SD of n = 2/group. The effect of 3-NBA treatment on the
expression levels of each gene was analyzed by a one-way ANOVA with a post-hoc
Dunnett’s multiple comparison test. Asterisks indicate a statistically significant difference
from the vehicle control (*p ≤ 0.05). HBEC3-KT cells were exposed to 1.25 µM 3-NBA
to assess whether exposure to 3-NBA led to recruitment of Nrf2 to the nucleus or
increased protein levels of ARE genes. Immunoblots revealed that 3-NBA had little
effect on Nrf2 localization in the nucleus and protein levels of AKR1C1-1C3 and
NQO1(B). A NQO1 activity assay was conducted HBEC3-KT cells after a 24 h of
exposure to 3-NBA (C). Bar graphs show mean ± SD of n = 2-3/group. These changes
were not statistically significant when tested by a one-way ANOVA with a post-hoc
Dunnett’s multiple comparison test.

114

5

DISCUSSION
5.1

Summary

Bacterial nitroreductases have been extensively characterized, but identification
and characterization of mammalian nitroreductases is relevant for understanding
susceptibility to environmental carcinogens.8,

13, 15

Nitroreductase activity in humans is

typically attributed to NQO1 and XO (Type I nitroreductases) or POR (Type II
nitroreductase).17 However, investigations of liver toxicity due to nitroaromatic prodrug
activation had demonstrated that other enzymes participate in the reduction of
nitroaromatic compounds.49-50 These nitroreductases were not identified in the original
study. It was recently reported that AKR1C3 exhibits nitroreductase activity towards
chemotherapeutic agent PR-104A,39 but no further work has been done to examine the
nitroreductase activity of human AKRs towards similar compounds. AKRs are an
important superfamily of enzymes that are broadly expressed throughout human tissues
and are best known for their ability to convert aldehydes and ketones to primary and
secondary alcohols.125 Identification of nitroreductase activity of AKRs towards
mutagenic NO2-PAHs would have major human health implications.
The major goal of this thesis was to determine whether human AKR enzymes could
exhibit nitroreductase activity towards 3-NBA, a representative NO2-PAH. NO2-PAHs
are an important component of diesel engine exhaust (DEE) that may drive lung cancer in
humans, and metabolic activation via nitroreduction is required for all NO2-PAHs to
exert their mutagenic effects.4 3-NBA was selected as a representative compound for my
thesis because it is the most mutagenic compound identified to date via the Ames
assay.109 3-ABA has been found in the urine of salt-mine workers who were
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occupationally exposed to diesel exhaust which indicates humans are exposed to 3-NBA
and can metabolize it.110 Prior research with 3-NBA identified that NQO1 is the major
nitroreductase, but this work was conducted in murine and human liver extracts which
may not be representative of bioactivation following inhalation exposures in human
lung.100
An intriguing feature of 3-NBA bioactivation is that it does not undergo
conjugation reactions for detoxification.

Sulfonation or acetylation reactions form

reactive esters and accelerate DNA adduct formation.98,
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Therefore, 3-NBA may

represent a class of environmental carcinogens that cannot be detoxified via
chemopreventive strategies that upregulate Nrf2 signaling. Glutathione conjugates of 3NBA metabolites have not been identified, and thus Nrf2 upregulation of glutathione
synthesis is unlikely to detoxify 3-NBA.4 Furthermore, given that AKRs and NQO1 are
among the most activated genes by Nrf2 signaling and part of the antioxidant response
gene battery, elevated Nrf2 signaling may exacerbate bioactivation of 3-NBA. The
second and third goals of my thesis were to assess how Nrf2 deletion or activation by
chemopreventive agents affected the toxication of 3-NBA.
5.1.1

The Role of Human Aldo-Keto Reductases in the Metabolic Activation of
the Carcinogenic Air Pollutant 3-Nitrobenzanthrone

The initial focus of my dissertation research was to investigate whether human
AKRs could exhibit nitroreductase activity towards 3-NBA. Cell-free discontinuous
assays were conducted with human recombinant enzyme and a NADPH regeneration
system. I found that AKR1C1-1C3 exhibited notable nitroreductase activity towards 3NBA, while AKR1C4, 1B10, 1D1, 7A2 and 7A3 exhibited negligible activity. AKR1A1
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and AKR1B1 exhibited zero nitroreductase activity over a 24 h incubation period.
Additional experiments were conducted with AKR1C1-1C3 to verify time- and proteindependent formation of 3-ABA. To verify that these enzymes catalyzed three successive
two-electron reductions and could be classified as Type I nitroreductases, I utilized
UPLC-HRMS to identify reaction intermediates. Both the nitroso and hydroxylamino
intermediates were detected, but these intermediates were not produced in significant
quantities, suggesting that these intermediates are unstable or are quickly metabolized to
3-ABA.
To compare the catalytic efficiencies of AKR1C1-1C3 and NQO1, the formation of
3-ABA was monitored as a readout of nitroreductase activity since it was a stable
product. Kinetic parameters were calculated from v vs. [S] curves constructed with each
protein under conditions where 3-ABA formation was linear with time and protein
amount. Catalytic efficiencies (kcat/Km) were roughly equivalent for AKR1C1, AKR1C3,
and NQO1 (~7 to 8 min-1 mM-1) while AKR1C2 possess a much lower kcat/Km value
(3.63 min-1 mM-1). This is the first time that AKR1C1 and AKR1C2 have been
recognized as nitroreductases towards any nitroaromatic substrate. The turnover rate (kcat)
of NQO1 was much higher than that of the AKR1Cs indicating a greater turnover (0.058
vs. 0.012 min-1), but AKR1Cs possess much lower Km values than NQO1.
To determine whether these enzymes act as nitroreductases in human lung cells in
vitro, I optimized a plate reader assay to measure the formation of 3-ABA. A549 and
HBEC3-KT cells were exposed to five different concentrations of 3-NBA ranging from
0.625 – 10 M and revealed time- and dose-dependent formation of 3-ABA. Using
specific inhibitors, I assessed the individual contribution of AKR1C1-1C3 and NQO1. I
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monitored the formation of 3-ABA in the presence and absence of dicoumarol (a NQO1
inhibitor) and flufenamic acid (a pan-AKR1C inhibitor). Together, these enzymes
account for approximately 50% of the nitroreduction of 3-NBA, and AKR1C enzymes
make a significant contribution that is similar to that of NQO1 in both cell lines. The
combination treatment (dicoumarol + flufenamic acid) reduced 3-ABA formation up to
53%. Allopurinol (XO inhibitor) was included in the inhibitor screen which revealed that
XO played a minor role in 3-NBA nitroreduction (~10%). Specific inhibitors against each
AKR1C enzyme were also included in the screen. AKR1C1-1C2 were identified as the
primary AKR1C isoenzymes that activated 3-NBA in A549 cells while AKR1C3 was the
major contributor in HBEC3-KT cells.
These data identify that AKR1C enzymes exhibit nitroreductase activity towards
3-NBA that is similar to that of NQO1, and suggest that AKR1Cs can compete for the
reduction of 3-NBA in human lung epithelial cells.

5.1.2

Nrf2 Knockout by CRISPR-Cas9 Reduces Bioactivation of the Mutagenic
Air Pollutant 3-Nitrobenzanthrone

The second part of my dissertation involved the characterization of A549 cell lines
that possessed heterozygous and homozygous CRISPR-Cas9 knockout of Nrf2. Wildtype
A549 cells express maximal Nrf2 activity via an inactivating Keap1 mutation and thus
these three cell lines (A549 wt, Nrf2-Het, and Nrf2-KO) should represent high,
intermediate, and null levels of Nrf2 signaling. To validate the levels of Nrf2 activity in
these cell lines, I quantified accumulation of Nrf2 to the nucleus. Nrf2 levels were
reduced by 60% in the heterozygous knockout cell line and were not detectable in the
homozygous knockout. I verified that A549 wt, Nrf2-Het, and Nrf2-KO cell lines were
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unresponsive to Nrf2 activators by examining Nrf2 translocation to the nucleus and
measuring mRNA and protein levels of ARE-genes after exposure to SFN and CDDOIm. No changes were detected in AKR1C1-1C3 and NQO1 in response to the Nrf2
inducers. 3-NBA treatment also failed to change expression of these genes, so these three
cell lines posess three different levels of Nrf2 signaling that are unresponsive to
regulation by external stimuli.
The first major finding was that basal expression of AKR1C1-1C2 genes was
dependent on the presence of Nrf2 in A549 cells. Homozygous deletion of Nrf2 led to a
99.5% reduction of AKR1C1 transcript levels and a 98.7% reduction in AKR1C2
transcript levels. Very low levels of AKR1C3 were maintained but were reduced by
92.4%. On the other hand, NQO1 transcript levels were reduced by 68.3% in the
homozygous Nrf2 knockout. These changes were mirrored at the protein level.
AKR1C1/2 bands were nearly undetectable while AKR1C3 was reduced by 95%. NQO1
protein levels and enzyme activity levels were reduced by 70%.

Another notable

observation was that AKR1C1 was the most responsive to the heterozygous Nrf2
knockdown at the mRNA level and was reduced by 50%. No reduction was observed in
NQO1 expression. The heterozygous Nrf2 knockout differentially affected AKR1C1-1C3
and NQO1 at the protein level as well: protein levels of AKR1C1-1C3 were reduced by
approximately 50% and NQO1 levels were reduced by 18% in the immunoblot assay.
The NQO1 activity assay was a more sensitive assessment of NQO1 and revealed a 30%
decrease due to the heterozygous Nrf2 deletion.
The second major finding was that homozygous and heterozygous Nrf2 knockdown
decreased 3-NBA reduction to 3-ABA in a dose-dependent manner. Compared to A549
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wt cells, homozygous Nrf2 knockout led to approximately 80% reduction in total 3-ABA
formation and heterozygous Nrf2 knockout led to 53% in total 3-ABA formation. This
level of reduction in bioactivation was consistent across multiple doses of 3-NBA
treatment and shows a clear relationship between Nrf2 signaling and 3-NBA
bioactivation.
Lastly, the third major finding was that there was no difference in cytotoxicity
measurements between A549 wt and Nrf2-Het cells treated with 3-NBA. 3-NBA is
cytotoxic and promotes oxidative stress in cells,287 but it appears that constitutively active
Nrf2 signaling confers no additional benefits compared to intermediate levels of Nrf2.
No significant differences were detected between A549 wt cells and A549 Nrf2-Het cells
exposed to 1.25 µM or 10 µM 3-NBA. As expected, the homozygous knockout of Nrf2
increased cytotoxicity measured through decreased viability and increased percentage of
cell death, but only during exposures to the high dose of 3-NBA (10 µM). This signifies
that loss of Nrf2 regulation of the antioxidant response may not be deleterious at low,
environmentally relevant concentrations of 3-NBA.
These data indicate that A549 wt, Nrf2-Het, and Nrf2-KO cell lines are a valuable
tool to study the effect of Nrf2 signaling on NO2-PAH bioactivation. Nrf2 ablation
substantially reduced the formation of the final reduction product 3-ABA which suggests
that high levels of Nrf2 may promote enhanced toxication of these compounds and
subsequent mutagenesis.

120

5.1.3

Nrf2 Induction of the Antioxidant Response Increases Bioactivation of the
Mutagenic Air Pollutant 3-Nitrobenzanthrone in Human Bronchial
Epithelial Cells

The third part of my dissertation characterized the effects of Nrf2 signaling on the
metabolic activation of 3-NBA in a non-transformed human bronchial epithelial cell line
(HBEC3-KT). These cells are the best model for normal human lung epithelial cells and
they possess intact Keap1 regulation of Nrf2 signaling. Key discoveries are summarized
below.
First, basal expression of AKR1C1 was significantly higher than AKR1C2-1C3 and
NQO1. AKR1C1 also underwent the highest induction by the Nrf2 activators SFN and
CDDO-Im (16.2-fold increase due to 10 µM SFN and a 13.5-fold increase for 50 nM
CDDO-Im). This was much higher than the induction of NQO1 expression which
underwent 4.9-fold and 6.45-fold increases with SFN and CDDO-Im, respectively. These
large changes in transcripts are not observed at the protein level. Functional increases in
protein level ranged from 1.8-fold to 2.6-fold for AKR1C1-1C3 and 2.2-fold for NQO1.
These data signify that AKR1C1 is the best biomarker of Nrf2 activity at the mRNA level
in this cell line. NQO1 and AKR1C1-1C3 undergo a similar magnitude of induction at
the protein level and any of them could be used to monitor Nrf2 induction in these cells.
Second, 3-NBA metabolism was evaluated in HBEC3-KT cells following
pretreatment with either DMSO, SFN, or CDDO-Im to induce AKR1C1-1C3 and NQO1.
Both Nrf2 activators led to statistically significant increases in 3-NBA toxication in
HBEC3-KT cells and increased 3-ABA formation by 40 – 60% across multiple doses of
3-NBA. This is likely due to increases in AKR1C1-1C3 and NQO1 protein levels which
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collectively account for 50% of the total nitroreductase activity towards 3-NBA in
HBEC3-KT cells. It is unlikely that 3-NBA treatment led to any additional increases in
AKR1C1-1C3 and NQO1 transcription which could have increased 3-NBA bioactivation
during metabolism experiments. Exposure to 1.25 µM to 10 µM 3-NBA had no
significant effect on AKR1C1-1C3 mRNA levels, and only exposure to 10 µM 3-NBA
could increase NQO1 transcript levels by 2.8-fold after 16 h of exposure. These modest
changes in NQO1 mRNA levels had no effect on NQO1 enzyme activity.
Finally, cell viability and percentage of cell death were measured to assess
cytotoxicity of 3-NBA treatment following pretreatment with SFN or CDDO-Im. Nrf2
activators have been designed as chemopreventive agents and have been previously
shown to reverse losses in viability due to oxidative stress.288 However, they had no
effect on cytotoxicity measurements in HBEC3-KT cells exposed to low or high doses of
3-NBA. Cells treated with 1.25 µM and 10 µM 3-NBA experienced twice as much cell
death which indicates 3-NBA was cytotoxic. However, there was no difference in
viability or cell death between cells pretreated with Nrf2 activators vs. DMSO regardless
of 3-NBA treatment group.
These data indicate that two different classes of Nrf2 activators (isothiocyanate
SFN and synthetic triterpenoid CDDO-Im) upregulated AKR1C1-1C3 and NQO1 in a
dose-dependent manner and led to subsequent increases in 3-NBA activation in vitro.
Despite their potential use as chemopreventive agents, they did not reduce cytotoxicity of
3-NBA.
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5.2
5.2.1

Discussion

AKR1C Enzymes Are Underappreciated Nitroreductases

I have shown that AKR1C1-1C3 act as nitroreductases towards 3-NBA. This is the
first time that AKR1C1 and 1C2 have been recognized as nitroreductases and the second
time that nitroreductase activity has been reported for AKR1C3.38 The apparent catalytic
efficiencies for reduction of 3-NBA by AKR1C1, AKR1C3, and NQO1 were equivalent.
This is notable given that NQO1 is considered the ‘gold standard’ for mammalian
nitroreductases and was identified as the primary nitroreductase for 3-NBA prior to this
thesis.111
Although they were not the focus of this study, human recombinant AKR1C4,
AKR1B10, AKR1D1, and AKR7A2-7A3 displayed very weak nitroreductase activity
towards 3-NBA. It is possible that these enzymes could possess higher activity towards
other nitroaromatics and they should not be ignored in future nitroreductase screens. The
human AKRs may have other nitroaromatic substrates, including carcinogenic NO2PAHs (e.g., 6-NC or 1,8-dinitropyrene) or nitrated prodrugs which are under
development for directed enzyme prodrug therapies. Nitroreductase activity of AKRs
against nitroaromatic prodrugs could pose challenges to antibody-directed enzyme
prodrug therapy (ADEPT) and gene- (or virus-) directed enzyme prodrug therapy
(GDEPT or VDEPT) strategies because they are ubiquitously expressed in human tissues
which could lead to systemic toxicity. This finding also broadens our definition of
mammalian Type I nitroreductases to include the AKR1C enzymes, despite their
dissimilarity to NQO1 and XO. NQO1 is a 30 kDa flavoenzyme that acts as a quinone
reductase or nitroreductase via a ping-pong kinetic mechanism and requires FAD as a
cofactor. XO is a large enzyme (270 kDa), and each dimer has one molybdopterin, two
123

iron sulfur centers, and one FAD.290-291 In a similar fashion to NQO1, it acts via pingpong mechanism. AKRs are not flavoenzymes and catalyze nitroreduction via an ordered
bi-bi kinetic mechanism. This indicates that mammalian Type I nitroreductases are
structurally and mechanistically diverse.
5.2.2

Competing Roles of AKR1Cs and NQO1 in 3-NBA Reduction in Human
Lung Cells
NQO1 and AKR1C1-1C3 are likely the two major nitroreductases in human lung.

The relative expression of NQO1 and AKR1C1-1C3 may play a role in determining their
overall contribution to 3-NBA bioactivation. Notably, the Km of AKR1C1-1C3 was much
lower than that of NQO1, indicating that the AKR1C enzymes may be more important
than NQO1 at the low concentrations of 3-NBA to which humans are exposed. In vitro,
the activity of NQO1 superseded any individual AKR1C isoform against 2.5 µM 3-NBA.
However this is much higher than the expected environmental concentration of 3-NBA.
NO2-PAHs are in the pg m-3 range in the environment and are 1 – 3 orders of magnitude
lower than those of related PAHs.72-73 It is difficult to estimate the concentration of 3NBA in lung tissue of exposed individuals because NO2-PAHs are adhered to particulate
matter which can accumulate in the epithelia of trachea and bronchial regions.74
NQO1 has an important polymorphic variant which may cause AKR1C1-1C3 to
be the primary nitroreductase against 3-NBA in certain populations. An inactivating
609C→T polymorphism in the NQO1 gene (rs1800566, Pro187Ser) which obliterates
NQO1 enzyme activity is prevalent in Asian populations.292 Compared with the wild-type
CC genotype carriers, the homozygous TT genotype carriers have only 2–4% NQO1
activity remaining.293 Approximately 4.4% of Caucasians, 5.2% of African Americans,
15.5% of Hispanics, 18.8% of Koreans, and 22.4% of Chinese populations possess the
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homozygous TT genotype.292 Up to 40% of Caucasians, 34% of African Americans, 52%
of Hispanics, and 48% of Asian populations possess the heterozygous CT genotype of
NQO1 which exhibits three-fold lower enzyme activity.292,

294

Therefore, even when

NQO1 is the single most efficient nitroreductase for a particular substrate, it is important
to identify the major nitroreductases that will dominate in the absence of wildtype NQO1.
AKR1C enzymes may become the major nitroreductase in this context, but other
candidates such as XO and POR should be considered.

5.2.3

Phantom Nitroreductases
Using specific inhibitors, I determined that AKR1C1-1C3 and NQO1 contribute

to 45 – 57% of the nitroreductase activity against 3-NBA in A549 cells and 53 – 73% in
HBEC3-KT cells. The conservative estimate is derived from treating cells with a
combination of dicoumarol and flufenamic acid, an NQO1 inhibitor and pan-AKR1C
inhibitor, respectively. The higher estimate in this range is derived from summing the
inhibition from each single inhibitor. Up to 10% of 3-NBA nitroreduction could be
inhibited by allopurinol, an inhibitor against XO,295 and another 10% could be inhibited
by rotenone, an inhibitor against Complex I which would eliminate mitochondrial
nitroreductases as a major source of nitroreduction.296-297 This leaves approximately 30%
of the total nitroreductase activity unaccounted for.
It is possible that Type II nitroreductases account for the other 30% of 3-NBA
reduction, such as POR. However, previous work by Arlt and colleagues reveals that
there is no difference in 3-NBA-derived DNA adduct formation in liver extracts from
wildtype and conditional knockout POR-null mice, suggesting that POR does not exhibit
significant nitroreductase activity towards 3-NBA.97 It is possible that POR could
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contribute in human lung, but there is no straightforward method available to inhibit POR
in this in vitro model. Other Type II nitroreductases such as nitric oxide synthase,
cytochrome b5 reductase, and aldehyde oxidase have not been investigated and could
possibly contribute to the bioactivation of 3-NBA.
It is also possible that there are unidentified Type I nitroreductases in human lung
cells that activate 3-NBA. There could be a single unidentified nitroreductase that
possesses similar nitroreductase activity compared to AKR1C1-1C3 or NQO1, but it is
more likely that several enzymes contribute a small percentage of the total nitroreductase
activity. An alternative explanation could be that these specific inhibitors were not the
best approach for this in vitro methodology and I could have underestimated the
contribution of AKR1C1-1C3 and NQO1. I screened six concentrations between 0 – 100
µM for each inhibitor to determine the lowest concentration in which they produced
maximal inhibition of 3-ABA formation. In every case, final inhibitor concentrations
were in excess of twice their IC50 values. However, these inhibitors could be actively
pumped out of cells or metabolized to inactive products. Future screens against 3-NBA
and other NO2-PAHs should be conducted with siRNA or CRISPR-Cas9 mutation
strategies to provide a better estimation of the individual enzyme contributions.
5.2.4

ARE-induction of AKR1C1-1C3 and NQO1 in human lung
Historically, NQO1 and heme oxygenase-1 (HMOX1) genes were widely used as

biomarkers of Nrf2 signaling, but recent studies have begun to use AKR1C1, AKR1C3,
and AKR1B10 as biomarkers of Nrf2 induction.158 Nrf2 induction of the ARE-gene
battery has not been previously investigated in HBEC3-KT cells, but my results are
similar to what has been reported for keratinocytes, renal epithelial cells, and human
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breast epithelial cells.152-154 A key difference is that AKR1C3 induction was quite low in
HBEC3-KT cells compared to other human epithelial cell lines.
In renal epithelial HK-2 cells treated with SFN, AKR1C1 transcripts were
upregulated by 2.54-fold and NQO1 transcripts by 2.52-fold.153 These changes are quite
modest compared to our maximal fold changes, but this study used much lower
concentrations of SFN (1.25 – 2.5 µM). I observed maximal changes at 10 µM SFN, but
found similar induction levels after treatment with 2 µM SFN (3.70-fold increases in
AKR1C1 and 2.61-fold increases in NQO1). In breast MCF10A and MCF12A cells,
AKR1C1/2 was induced by 14.8-fold following exposure to 10 µM SFN.154 This is the
only other study that has monitored changes at the protein level, but they used stable
isotopic labeling with amino acids in culture (SILAC) rather than immunoblot and
enzyme activity measurements. Agyeman and colleagues reported a 30.7-fold increase in
AKR1C1/2 protein levels.154 In these cell lines, AKR1C3 was highly inducible and
experienced a 27.0-fold increase at the mRNA level and a 39.3-fold increase at the
protein level. Changes in NQO1 were lower: a 4.4-fold increase in transcript levels was
measured via microarray and a 3.7-fold increase in protein was measured by SILAC.154
The effect of Nrf2 activators has not been explored in human keratinocytes, but Keap1
suppression with siRNA methods downregulated AKR1C1 transcript levels by 14.4-fold,
AKR1C3 by 15.4-fold, and NQO1 by 2.4-fold.152
My work in HEBC3-KT cells has the advantage that I measured absolute levels of
AKR1C1-1C3 and NQO1 at the level of copy number in addition to fold changes. This
allows comparison of basal gene expression in addition to magnitude of upregulation.
However, I did not observe good correlation between mRNA and protein levels of these
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genes in HBEC3-KT cells. There may be a number of explanations for this, including
differences in the t1/2 of mRNA transcripts vs. corresponding protein, miRNA regulation
of mRNA to prevent translation, and post-translational modification of proteins that
affect function and stability. Furthermore, the qPCR primers used in this study do not
have the ability to distinguish between full length transcripts and splice variants which
may account for the much higher levels of mRNA transcripts that are not observed at the
protein level. AKR1C1 has five splice variants in humans, three of which are protein
coding; AKR1C2 has 10 splice variants, four of which are protein coding; AKR1C3 has
11 splice variants, four of which are protein coding; and NQO1 has seven splice variants,
six of which are protein coding.
These data suggest that protein measurements are necessary to validate gene
expression changes due to Nrf2 activators and determine whether they are functionally
relevant. Correlation between mRNA and protein levels due to Nrf activators may vary
depending on tissue-specific responses. Using mRNA levels to predict protein changes
would overestimate protein levels of AKR1C1-1C3 in human bronchial epithelial cells
and would underestimate protein levels in human breast epithelial cells. These findings
are not surprising given that prior studies have also found poor correlation between
mRNA expression and protein levels (R2: 0.29-0.43).286, 298
5.2.5

3-NBA Bioactivation: A New Dark Side for Nrf2?
A common strategy for chemoprevention is the reduction of DNA damage by

stimulating detoxification of reactive metabolites formed from procarcinogens.189-190
There has been considerable interest in the development of Nrf2 activators as
chemopreventive agents given that elevated Nrf2 signaling upregulates genes involved in
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antioxidant synthesis, conjugation enzymes, and drug transporters. Nrf2 is able to
stimulate enhanced detoxification of carcinogens such as benzene, acrolein, and aflatoxin
B1 via conjugation with glutathione.185, 299
However, a dark side of Nrf2 signaling emerged when multiple groups reported
that Nrf2 signaling was constitutively active in several cancer types.205, 216, 300 Elevated
Nrf2 signaling promotes cancer cell survival and confers chemoresistance.205, 261, 282, 301303

Metabolic reprogramming due to ARE-gene induction accelerates cellular growth and

proliferation.276, 280 The most striking example of how Nrf2 signaling plays dual roles in
cancer is seen following short- and long-term observations of mice exposed to urethane.
Although Nrf2−/− mice developed a large number of urethane-induced lung micronodules
in the early phase after urethane administration (4 or 8 weeks), wildtype mice exhibited
increased tumor frequency and size at later observation times (24 weeks). This indicates
that the proliferative potential of Nrf2 induction may outweigh its short-term benefits in
carcinogen detoxication.
In this thesis, I proposed a new dark side to Nrf2 signaling in the context of
chemoprevention: Nrf2 may be deleterious during the metabolic activation of certain
carcinogens such as 3-NBA that are bioactivated by members of the ARE-battery and do
not undergo GST-mediated detoxification.

Elevated Nrf2 signaling increased

bioactivation of 3-NBA via upregulation of AKR1C1-1C3 and NQO1 in A549 and
HBEC3-KT cells due to genetic and pharmacological manipulation of Nrf2 signaling
which supports this hypothesis. Since 3-NBA metabolites do not undergo conjugation
reactions for excretion, these increases in nitroreduction are likely to promote buildup of
toxic metabolites that can interact with DNA. For example, Nrf2 signaling also
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upregulates SULT1A1 in humans,304 which may further accelerate DNA adduct
formation by further activating N-OH-3-ABA. If increased 3-NBA bioactivation
correlates to increased DNA adducts, this would promote mutagenesis. 3-NBA-derived
DNA adducts form at the C8 and N2 position of guanine and at the C8 and N6 position of
adenine in vitro and in vivo, and they typically result in G to T transversions.112 Further
work is required to measure 3-NBA-derived DNA adducts in A549 cell lines with Nrf2
knockout and HBEC3-KT cells with Nrf2 activators. Stable isotope labeled internal
standards will need to be synthesized in order to quantify changes in DNA adduct levels
in these cell lines.113
Previous work supports my hypothesis that Nrf2 signaling may drive changes in
carcinogen metabolism and affect DNA adduct burden. In breast epithelial MCF10A
cells, AKR expression was greatly enhanced by co-exposure to DEE and B[a]P when
compared to exposures with B[a]P alone.305 This was attributed to changes in Nrf2
signaling. DEE induces Nrf2 translocation to the nucleus and upregulates NQO1 and
AKRs in human cell lines.306-308 Co-exposure to DEE and B[a]P significantly decreased
stable PAH-DNA adduct levels and significantly increased 8-oxo-2'-deoxyguanosine (8oxo-dGuo) formation.305 This suggests that these cells experienced enhanced oxidative
DNA damage. Therefore, complex mixtures such as DEE may increase Nrf2 signaling
and modify the carcinogenic potency of PAHs by shifting the metabolic activation
pathway from the production of stable DNA adducts and elevate oxidative DNA lesions.
Further work is needed to fully understand whether Nrf2 activation may have deleterious
consequences during metabolic activation of NO2-PAHs to negatively impact cancer
prevention.
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5.2.6

Nrf2 Signaling and Cytotoxicity: Implications for Nrf2 Inhibitor Therapy
Constitutively active Nrf2 signaling due to a Keap1 mutation has been observed

in 30 – 60% of lung tumors and is associated with chemotherapy resistance and
aggressive tumors.205, 309-310 To counter this, Nrf2 inhibitors have entered clinical trials to
determine whether they can sensitize cancer cells to chemotherapeutic agents. 311 Highthroughput screens of small molecule libraries revealed that ML385 is a lead compound
that binds Nrf2 and inhibits ARE-gene expression.312 ML385 substantially enhances
cytotoxicity in NSCLC cells when used in combination with platinum-based drugs such
as doxorubicin or taxol compared to single agents alone.312
An interesting finding of my thesis was that homozygous knockout of Nrf2, but
not heterozygous knockout, enhanced cytotoxicity of 3-NBA in lung adenocarcinoma
A549 cells. 3-NBA is cytotoxic to cells, but the partial ablation of Nrf2 did not sensitize
Nrf2-Het cells to 3-NBA exposures compared to wildtype cells. These data suggest that
Nrf2 inhibitors will need to be very efficacious to impact cancer cell viability. A potential
application of the A549 cell line variants may be to characterize chemotherapeutics to
determine whether these compounds also require a complete deletion of Nrf2 to exert
maximal cell damage.

5.2.7

AKR1C Enzymes Are Important for Chemical Carcinogenesis
AKR1C enzymes play a clear role in the metabolic activation of 3-NBA, and they

may be involved in the bioactivation of other NO2-PAHs. This is intriguing as they have
already been recognized as important players in the metabolic activation of related PAHs.
PAHs also require metabolic activation to exert their mutagenic and tumorigenic effects.
Our group previously discovered that AKR1C1-1C3 catalyze the conversion of PAH
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trans-dihydrodiols to electrophilic and redox active PAH o-quinones.124, 313-314 Metabolic
activation of PAHs also produces diol-epoxides (DE) (cytochrome P450 (CYP)
1A1/CYP1B1-dependent) and radical cations (POR-dependent).124 The AKR-pathway is
unique in that its metabolites (catechol and o-quinone) can engage in futile redox-cycling
which promotes oxidative stress and formation of 8-oxo-dGuo. 8-oxo-dGuo can promote
G to T transversions, the dominant mutagenic lesion observed in K-ras and p53 in human
lung cancer.314-315
Given that AKR1Cs exhibit dihydrodiol dehydrogenase and quinone reductase
activity towards parent PAHs with a bay region, they may act as bifunctional enzymes in
the activation of more complex NO2-PAHs. For example, 6-NC possesses a bay region
and can form trans-dihydrodiols which mirrors metabolic activation of B[a]P.
Investigating the multiple pathways of AKR-mediated activation will be important to
understand the metabolic activation of these NO2-PAHs. Both PAHs and NO2-PAHs are
ubiquitous environmental contaminants that are enriched in DEE, urban air pollution, and
pollution near roadways. As a result, the response of AKRs to stress signals will be
important in these widespread exposure contexts. Induction of AKR1C genes may
exacerbate formation of 8-oxo-dGuo lesions from PAHs and may enhance metabolic
activation of NO2-PAHs. On the other hand, they simultaneous detoxify harmful
aldehydes (e.g. 4-hydroxy-2-nonenal) that result from decomposition of lipid
hydroperoxides. These lipid peroxides are formed after the overproduction of endogenous
ROS which can oxidize polyunsaturated fatty acids in cellular membranes.316 Therefore,
the induction of AKR1Cs may be a double-edged sword. The overall outcome of these
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exposures will depend on the concentrations of environmental contaminants, expression
of these enzymes, and downstream DNA adduct repair mechanisms.
5.3

Conclusions and Future Directions

Based on the work presented in this dissertation, I propose that AKR1C1-1C3 and
NQO1 compete in the metabolic activation of NO2-PAHs in humans. Approximately
50% of the total nitroreductase activity of human lung epithelial cells can be attributed to
these enzymes, but more work is required to identify the other nitroreductases that
bioactivate 3-NBA. AKR1C1-1C3 and NQO1 are part of the antioxidant response, and I
have demonstrated that pharmacological Nrf2 activation increases the expression of these
genes in human lung epithelial cells. These changes lead to increases in protein levels and
corresponding enzyme activity which results in 40 – 60% increases in 3-NBA reduction.
Phase II conjugation reactions with 3-NBA metabolites enhance DNA adduct formation
by providing a good leaving group that accelerates formation of a nitrenium-carbenium
tautomer. This electrophilic species binds DNA and forms bulky DNA adducts. As a
result, the elevated metabolic activation of 3-NBA is expected to increase DNA adduct
levels. Future work is required to synthesize stable isotope labeled DNA adduct standards
so that the effect of Nrf2 activators can be monitored in vitro.
Further work is also required to characterize other representative NO2-PAHs as
substrates for AKRs. The nitroreductase activity of AKR1C1-1C3 is largely unexplored,
and these enzymes may have other nitroaromatic substrates. It will also be relevant to
determine if these enzymes catalyze the metabolic activation of diverse NO2-PAHs,
including 1-NP, 6-NC, and 1,8-dinitropyrene. Notably, the dinitropyrenes may undergo
nitroreduction at one or both nitro groups to form bis-electrophiles.
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If AKR1Cs can reduce these representative NO2-PAHs, it will be important to
assess the effect of Nrf2 signaling on the toxication of diverse NO2-PAHs. The
relationship between Nrf2 signaling and 3-NBA bioactivation may be unique, or it may
be representative of a subset of NO2-PAHs substituted with a ketone group. The effect of
Nrf2 signaling on the metabolism of 1-NP and 6-NC may differ from 3-NBA because
these compounds undergo monooxygenation and form glutathione conjugates which aid
in their detoxification. In this context, the effects of pharmacological Nrf2 activation will
likely depend on the relative rates of NO2-PAH-derived DNA adduct formation vs.
glutathione conjugation.
Together, these data raise questions about the safety of indiscriminate use of Nrf2targeted chemoprevention therapies as there may be environmental exposures (diesel
exhaust, urban air pollution) that are toxified by elevated Nrf2 activity. Future human
studies with pharmacological Nrf2 activators should include biomarkers of diesel exhaust
exposure and effect to identify exposure contexts in which such agents are most helpful
or deleterious.
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6

MATERIALS AND METHODS

Caution: 3-NBA and its derivatives are potent mutagens and suspected carcinogens and
should be handled in accordance with NIH Guidelines for the Use of Chemical
Carcinogens.
6.1

Chemicals and reagents

3-NBA, N-OH-3-ABA, and 3-ABA were synthesized as described previously.243,
317-318

The synthesis of 3-NOBA was performed from 3-ABA following the experimental

protocol reported by Fifer et al. for the synthesis of similar nitroso-PAHs.319 The purity
and identity of these compounds were verified by UV spectroscopy, high resolution mass
spectrometry, and high-field 1H NMR spectroscopy. All other chemicals were of the
highest grade commercially available, and all solvents were of HPLC grade. (S)-(+)1,2,3,4-tetrahydro-1-naphthol

(S-tetralol),

flavin

adenine

dinucleotide

(FAD),

dithiothreitol (DTT), 1-acenaphthenol, dicoumarol (Dic), allopurinol, rotenone, and Dglucose-6-phosphate (G6P) were purchased from Millipore-Sigma (St. Louis, MO).
Glucose-6-phosphate dehydrogenase (G6PD) was purchased from Worthington
Biochemical Corporation (Lakewood, NJ). Flufenamic acid (FA), ursodeoxycholate, and
indomethacin were purchased from ICN Biomedicals, Inc. (Aurora, Ohio). 1-(2-Cyano3,12,28-trioxooleana-1,9(11)-dien-28-yl)-1H-imidazole (CDDO-Im) was purchased from
Tocris Bioscience (Bristol, UK) and R-sulforaphane (SFN) was purchased from LKT
Laboratories (St. Paul, MN).
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6.2
6.2.1

Enzyme Preparation

Preparation of AKR1C1-AKR1C4
Human recombinant enzymes AKR1C1-AKR1C4 were prepared and purified as

previously described.137 Each enzyme was shown to be homogenous by SDS-PAGE
analysis prior to use.320 The specific activities of AKR1C1 and AKR1C2 were
determined by measuring the formation of NADH and 1-acenaphthenone at 340 nm using
a Beckman DU640 spectrophotometer. A typical reaction system contained 200 μM 1acenaphthenol, 2.3 mM NAD+, and 4% acetonitrile (v/v) in 100 mM potassium
phosphate, pH 7.0. The specific activities of AKR1C1 and AKR1C2 were determined by
measuring the formation of NADH at 340 nm. A typical assay system for determining the
specific activity of AKR1C3 contained 3.0 mM (S)-(+)-1,2,3,4-tetrahydro-1-naphthol (Stetralol), 2.3 mM NAD+, and 4% acetonitrile (v/v) in 100 mM potassium phosphate, pH
7.0. Lastly, a typical assay system to determine the specific activity of AKR1C4
contained 75 μM andosterone, 2.3 mM NAD+, and 4% acetonitrile (v/v) in 100 mM
potassium phosphate, pH 7.0.
All enzymatic assays were incubated at 37 °C for 3 min followed by adding a
serial dilution of enzyme to initiate the reaction. After continuously monitoring for 5 min,
the increase in UV absorption was recorded to calculate the initial velocity and determine
specific activity for each enzyme. The specific activities of AKR1C1 and AKR1C2 for
the NAD+ dependent oxidation of 1-acenaphthenol were 1.8 and 2.6 μmol min−1 mg−1,
respectively. The specific activity of AKR1C3 for the NAD+ dependent oxidation of Stetralol was 3.0 μmol min−1 mg−1 and the specific activity of AKR1C4 for the
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NAD+ dependent oxidation of andosterone was 0.3 μmol min−1 mg−1. These specific
activities are in accord with previously measured values.134
6.2.2

Preparation of NQO1
Homogenous human recombinant NQO1 was purchased from Millipore Sigma (St.

Louis, MO). The specific activity of NQO1 was determined by measuring the reduction
of 40 μM DCPIP at 600 nm using a Beckman DU640 spectrophotometer. Typical
reactions contained 200 μM NADH, 0.7 mg/mL BSA, and 5 nM FAD in 25 mM TrisHCl, pH 7.4 at 25 °C. All assays were incubated at 25 °C for 3 min followed by adding a
serial dilution of enzyme to initiate the reaction. The specific activity of NQO1 under
these conditions was 985 μmol min−1 mg−1.

6.3

Discontinuous enzymatic assays

In order to identify whether AKR1C1-1C3 catalyzed the nitroreduction of 3-NBA,
enzymatic assays were prepared in a cell-free system. Typical assays to determine
catalytic efficiencies with AKR1C1-1C3 contained 1 – 30 μM 3-NBA, 4% DMSO (v/v),
and a NADPH regeneration system to maintain 1 mM NADPH in 50 mM potassium
phosphate buffer, pH 7.0. These reactions were maintained at 37 °C in the dark with
gentle agitation. The NADPH regeneration system consisted of 1 mM G6P, 1 mM
NADP+, and 2 units mL−1 G6PD. The reactions with AKR1C1-1C3 were initiated with
0.5 μM enzyme. Typical reaction mixtures with NQO1 contained 1 – 30 μM 3-NBA, 1
μM FAD, 1 mM DTT, and a NADPH-regeneration system in 50 mM potassium
phosphate buffer, pH 7.0. Reactions were initiated with 0.25 μM enzyme and maintained
in the dark at 37°C with gentle agitation. The amount of enzyme used was always in the
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linear range for each protein as determined by plots of initial velocity versus enzyme
concentrations. In control reactions, AKR1C1-1C3 or NQO1 was omitted from the
mixtures. Reactions for each substrate concentration were repeated 3 to 5 times.
To stop enzymatic reactions, aliquots were extracted twice with 1.5-fold volume of
ice-cold ethyl acetate saturated with H2O. Samples were vortexed vigorously for  20 sec
and centrifuged at 16,000 × g to help phase separation. The organic phase was then
collected and dried under vacuum with a SpeedVac concentrator (Thermo Fisher
Scientific, San Jose, CA). The residue was re-dissolved in methanol for analysis by UVHPLC. 3-ABA was identified by its retention time and UV spectra which were compared
to authentic standards and quantified using calibration curves. Amounts of 3-ABA (nmol)
were plotted against time and the initial velocity was estimated by the slope of the linear
portion of the progress curve in the first 5 – 10% of the reaction. Velocity vs. substrate
concentration curves were analyzed using GraphPad Prism Version 7 (GraphPad
Software, La Jolla, CA) to calculate Vmax, Km, and kcat.
6.4

UV-HPLC analysis

Data were acquired using a Waters Alliance 2695 HPLC system (Waters
Corporation, Milford, MA) coupled to a Waters Alliance 2996 Photodiode Array
Detector (Waters Corporation, Milford, MA). Separations were accomplished on a
reverse-phase (RP) column (Zorbax-ODS C18, 5 μm, 4.6 mm × 250 mm) (Dupont Co.,
Wilmington, DE) with a guard column at ambient temperature. The mobile phase
consisted of 5 mM ammonium acetate and 0.1% trifluoroacetic acid (TFA) (v/v) in H2O
(solvent A) and 5 mM ammonium acetate and 0.1% TFA (v/v) in acetonitrile (solvent B)
and was delivered at a flow rate of 0.5 mL/min. The linear gradient elution program was
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as follows: 5% to 95% B over 30 min, followed by an isocratic hold at 95% B for another
10 min. At 40 min, B was returned to 5% in 1 min and the column was equilibrated for
19 minutes before the next injection. The total run time for each analysis was 60 min.
6.5

Liquid chromatography high resolution mass spectrometry (LC-HRMS)

For LC-HRMS analysis, enzymatic reactions were prepared as above: aliquots were
extracted twice with 1.5-fold volume of ice-cold ethyl acetate saturated with H2O and
centrifuged at 16,000 × g to help phase separation. The organic phase was dried under
vacuum with a SpeedVac concentrator. The residue was re-dissolved in 50% methanol in
water and cleaned up by passage through a CoStar Spin-X HPLC 0.2 µm nylon filter
(Corning Incorporated, Coning, NY). 5 μL aliquots were analyzed on a Waters nanoAcquity Ultra Performance

Liquid

Chromatography (UPLC)

system

(Waters

Corporation, Milford, MA) coupled to a QE-HF mass spectrometer (Thermo Fisher
Scientific, San Jose, CA). Separations were accomplished on an analytical column (C18,
1.7 µm BEH130, 150 µm × 100 mm) (Waters Corporation, Milford, MA) at 55 °C. The
mobile phase consisted of 0.1% formic acid (v/v) in H2O (solvent A) and 0.1% formic
acid (v/v) in acetonitrile (solvent B) and was delivered at a flow rate of 1.6 µL/min. The
linear gradient elution was as follows: an isocratic hold at 5% B for 5 min, 5% to 95 % B
over 30 min, followed by an isocratic hold at 95% B for another 10 min. At 46 min, B
was returned to 5% in 2 min and the column was equilibrated for 12 min before the next
injection. The total run time for each analysis was 60 min. The mass spectrometer was
operated in the positive ion mode, with a Microm source after system calibration with the
manufacturer’s calibration mixture. The ionization voltage was set to 1.5 kV and the
capillary temperature was set to 200 °C. Full scan spectra were acquired with a resolving
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power of 120,000 in a mass range from m/z 100 to 800. The Xcalibur software version
2.0 (Thermo Fisher Scientific, San Jose, CA) was used to control the UPLC-MS/MS
system and to process data.
6.6

Cell Culture

The adenocarcinoma human alveolar basal epithelial cell line A549 was obtained
from the American Type Culture Collection (ATCC, Manassas, VA; ATCC #CCL-185)
and cultured in Kaighn's Modification of Ham's F-12 Medium (F-12K) supplemented
with 10% fetal bovine serum, 100 units/mL penicillin, and 100 µg/mL streptomycin.
A549 cells were passaged every 4 days at a dilution of 1:7. Human bronchial epithelial
cells (HBEC3-KT) were a kind gift from Dr. John Minna at the University of Texas
Southwestern Medical Center and have been immortalized via the overexpression of
cyclin-dependent kinase 4 (Cdk4) and human telomerase reverse transcriptase (hTERT).
HBEC3-KT are considered the best model for normal HBEC cells as they do not form
colonies in soft agar or tumors in nude mice (Ramirez et al. 2004). HBEC3-KT cells
were maintained in Keratinocyte-SFM supplemented with human recombinant Epidermal
Growth Factor and Bovine Pituitary Extract. HBEC3-KT cells were passaged every 5
days at a dilution of 1:4. All cells were cultured in an atmosphere of 95% air and 5% CO2
at 37°C in 100 mm culture plates. Cultured cells with a passage number of 5−20 were
used in the experiments to reduce variability due to cell culture. Cells were routinely
authenticated by short-terminal repeat DNA analysis and were mycoplasma-free (DNA
Diagnostics Center Medical, Fairfield, OH).
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6.7

Developing NRF2 Knockout A549 Cell Lines

A549 cells with homozygous knockout (A549 Nrf2-KO) and heterozygous
knockout (A549 Nrf2-Het) of the endogenous NFE2L2 gene, which encodes Nrf2,
were kindly provided by Laureano de la Vega from the University of Dundee. Briefly,
these cell lines were created by transfecting A549 cells with pLentiCRISPR-v2
(Addgene plasmid #52961) containing a guide RNA directed against the gene
sequence

for

the

Neh2

domain

within

the NFE2L2 locus

(5′-TGGAGG

CAAGATATAGATCT-3′), which encodes amino acids that bind KEAP1. NRF2
homozygous and heterozygous knockout clones were those in which the Cas9mediated cleavage was repaired out-of-frame. After 2 days of puromycin selection,
cells were clonally selected by serial dilution, and positive clones were identified as
previously described.321 Control cells, referred as A549 ‘wildtype’ (A549 wt), are the
pooled population of surviving cells transfected with an empty pLentiCRISPRv2
vector treated with puromycin. These cell lines were authenticated by STR profiling and
verified to be mycoplasma-free prior to use.
6.8

Detection of 3-ABA Formation in Cell Culture

The fluorescence of 3-ABA was used to measure the uptake and nitroreduction of
non-fluorescent 3-NBA in cell culture. I adapted a 96-well fluorescence detection of 3ABA that has been previously reported (Pink et al. 2017). To assess the contribution of
Nrf2 signaling in the metabolic activation of 3-NBA, experiments were conducted in
multiple A549 cell line variants (A549 wildtype, A549 Nrf2-Het, and A549 Nrf2-KO).
Metabolic assays with A549 cell lines were performed in 96-well plates 24 h (± 2 h) after
seeding of 1 × 104 A549 cells per well. After allowing 24 h for cells to attach, they were
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treated with 3-NBA in 0.1% DMSO (1.25 – 10 μM 3-NBA) in phenol red-free DMEM/F12 (Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12). 3-NBA Excitation (λex)
and emission (λem) wavelengths for the Synergy 2 multi-detection microplate reader
(Biotek Instruments Inc., Winooski, VT) were set at 520 and 650 nm, respectively, based
on the spectral properties of 3-ABA. Cells treated with cell culture medium that
contained 0.1% DMSO were used to correct for auto-fluorescence of the cells.
Spontaneous formation of 3-ABA was monitored in blank wells to determine background
conversion rates of 3-NBA to 3-ABA in a cell-free environment but were found to be
non-significant. Formation of 3-ABA (pmol) was quantified by using calibration curves
constructed with authentic standards in phenol red-free DMEM/F-12 media.
Measurement of nitroreduction in HBEC3-KT cells was performed in 96-well
plates by plating 2 x 104 cells which were allowed to recover for 24 h to allow them to
attach, before they were treated with Nrf2 activators (2.5 – 100 nM CDDO-Im or 0.625 –
10 µM SFN) or vehicle control (0.05% DMSO) for 48 h. Media was then replaced with
fresh phenol red-free K-SFM containing 1.25 – 10 µM 3-NBA in 0.1% DMSO.
Formation of 3-ABA (pmol) was quantified by using calibration curves constructed with
authentic standards in phenol red-free K-SFM.
To assess the contribution of individual enzymes, cells were treated with specific
inhibitors prior to and throughout the duration of exposure to 3-NBA. The following
inhibitors were selected: dicoumarol, NQO1 inhibitor;322 flufenamic acid, pan-AKR1C
inhibitor;323 salicylic acid, AKR1C1 inhibitor;324-325 ursodeoxycholate, AKR1C2
inhibitor;326 indomethacin, AKR1C3 inhibitor;327 allopurinol, XO inhibitor;295 and
rotenone, Complex I inhibitor296-297 to eliminate the contribution of mitochondrial
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nitroreductases. To determine the optimal treatment conditions, six concentrations
between 0 – 100 µM were tested for each inhibitor to determine the lowest concentration
in which they produced maximal inhibition of 3-ABA formation. All assays were
conducted in the 96-well assays as described above with 2.5 µM 3-NBA. Cells were
pretreated with inhibitors in 0.1% DMSO or vehicle control (0.1% DMSO) for 1 h prior
to exposure to 3-NBA. After the 1 h incubation, cells were treated with 2.5 µM 3-NBA +
the inhibitor in 0.15% DMSO. Control cells were exposed to inhibitor only (0.15%
DMSO) and used as blanks to correct for cellular auto-fluorescence. I measured the effect
of inhibitors on 3-ABA formation at 6 h for A549 cells and 24 h for HBEC3-KT cells.
These time points were taken during a linear period of 3-ABA formation and within the
linear range of the calibration curves for 3-ABA detection in the respective cell media.
6.9

Quantification of mRNA expression by RT-PCR

Total RNA was isolated using RNeasy kit (Qiagen, Hilden, Germany) according to
the manufacturer’s protocol and samples were treated with RNase-free DNase (Qiagen,
Hilden, Germany). RNA yield and purity were then measured spectrophotometrically at
260 nm using a Nanodrop ND-2000 spectrophotometer (Thermo Fisher Scientific,
Waltham, MA). 1 µg of total RNA was reverse transcribed to cDNA using the High
Capacity RNA to cDNA kit (Applied Biosystems, Foster City, CA). Resulting cDNA
samples were analyzed using QuantiTect SYBR Green PCR Master Mix (Qiagen, Hilden,
Germany) in the Chromo4 System (BioRad, Hercules, CA). Oligonucleotide primers
specific to human AKR1C1, AKR1C2, AKR1C3, NQO1, and GAPDH are described in
Table 6.1 and have been previously validated.328
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The conditions for the real-time PCR were as follows: 95°C for 15 min followed by
40 cycles of 94°C for 15 sec, X°C (annealing temperature) for 30 sec and 72°C
(extension temperature) for 30 sec (whereby X = 57°C for AKR1C1; 58°C for GAPDH;
59°C for NQO1; and 61°C for AKR1C2 and AKR1C3. Data analyses were based on
quantifying fg levels for each transcript using standard curves constructed with fulllength standards (2,500,000 to 0.025 fg) as previously described by us.328 The RT-PCR
method for each transcript was linear (r = 0.995) over a dynamic range (109) as
determined by plotting the log10 fluorescence intensity vs. the number of cycles. Fulllength standards (2,500,000 to 0.025 fg) were generated for AKR1C1, AKR1C2, AKR1C3,
and NQO1 from their appropriate cDNA plasmids (pcDNA3-AKR1C1, pcDNA3AKR1C2, pcDNA3-AKR1C3, pkk233-2-NQO1). PCR product standards (2,500,000 to
0.025 fg) were generated for GAPDH with the following: forward primer, 5’TCCTCCTGTTCGACAGTCAG-3’,

and

reverse

primer,

5’-

CACAGACACCCCATCCTATC-3’. All samples were analyzed in triplicate and
amounts of the target cDNA (femtograms) were corrected by amplicon length so that
copy number of each gene was determined. The resulting values were subsequently
normalized to the amount of GAPDH.
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Table 6.1. Primer sequences designed for each gene
Gene

Forward qPCR Primer

Reverse qPCR Primer

Amplicon Length (bp)

AKR1C1

GTAAAGCTTTAGAGGCCAC

ATAAGGTAGAGGTCAACATAA

249

AKR1C2

GTAAAGCTCTAGAGGCCGT

CTGGTCGATGGGAATTGCT

179

AKR1C3

AAGTAAAGCTTTGGAGGTCACA

GGACCAACTCTGGTCGATGAA

185

NQO1

TCCCCCTGCAGTGGTTTGGAGT

ACTGCCTTCTTACTCCGGAAGGGT

127

GAPDH

CATCTCTGCCCCCTCTGCTGA

GGATGACCTTGCCCACAGCCT

305
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6.10 Immunoblotting
Nuclear and cytosolic extracts were prepared with the NE-PER nuclear extraction
kit according to the manufacturer's protocol (Pierce Biotechnology, Rockford, IL).
Protein concentrations were determined with a BCA Assay Kit (Pierce Biotechnology,
Rockford, IL).
Nuclear and cytosolic proteins (25 μg) were resolved electrophoretically using 10%
(w/v) SDS polyacrylamide gels. Gels were electroblotted onto nitrocellulose membranes
and blocked with 5% (w/v) non-fat milk in phosphate-buffered saline containing 0.05%
Tween-20 (PBS-T). Blots were then incubated with primary antibodies overnight at 4°C.
Antibodies used in this study were as follows: murine anti-human Nrf2 (ab62352;
Abcam, Cambridge, UK); rabbit monoclonal anti-human AKR1C1/1C2 (ab179448;
Abcam, Cambridge, UK); murine monoclonal anti-human AKR1C3 (Millipore Sigma,
St. Louis, MO); murine monoclonal anti-human NQO1, a kind gift from David Ross at
the University of Colorado; murine monoclonal anti-human Lamin-A (sc7148; Santa
Cruz Biotechnology, Dallas, TX); and murine monoclonal α-Tubulin (NB100-690;
Novus Biologicals, Centennial, CO). Blots were washed in PBS-T and incubated with
species-appropriate secondary antibody conjugated with horseradish peroxidase (1:1500
dilution) in 5% non-fat milk in PBS-T buffer for 1 h at room temperature. Proteinantibody complexes were detected using enhanced chemiluminescence (Pierce
Biotechnology, Waltham, MA) and imaged with a ChemiDoc MP Imaging System (BioRad Laboratories, Hercules, CA). Band intensity was quantified by Image Lab software
(Bio-Rad Laboratories, Hercules, CA). Lamin-A was used as a loading control for
nuclear fractions while α-Tubulin used as a loading control for cytosolic proteins.
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6.11 NQO1 Activity Assay
NQO1 activity was quantified as described previously (Fahey et al. 2004). A549
wt, Nrf2-Het, and Nrf2-KO cell lines were seeded at a density of 1 x 104 cells per well
and cultured overnight. After 24 h, the medium was decanted, and the cells were
incubated with 75 μL of lysis solution (0.8% (w/v) digitonin in 2 mM of EDTA) for 15
min at 37°C. Aliquots (20 µL) from each well was transferred to another 96-well plate for
protein quantification with a BCA Assay Kit (Pierce Biotechnology, Rockford, IL). A
reaction mixture was prepared as follows: 1 mL of 1 M Tris-HCl (pH 7.4), 26.7 mg of
bovine serum albumin, 270 mL of 1.5% Tween-20, 202 μL of 1 mM FAD+, 270 mL of
150 mM glucose 6-phosphate, 24 μL of 50 mM NADP+, 80 units of yeast glucose 6phosphate dehydrogenase, 12 mg of MTT, 40 μL of 50 mM menadione (added
immediately before use), and milliQ water to a volume of 40 mL. 200 μL of the reaction
mixture was added to each well and incubated for 5 min, and the reaction was stopped by
adding 50 μL of 0.3 mM dicoumarol solution (in 0.5% DMSO and 5 mM potassium
phosphate, pH 7.4). Absorbance at 610 nm was measured with a Synergy 2 multi-mode
plate reader (BioTek, Winooski, VT). To control for nonspecific quinone reductase
activity, matched blanks for each treatment group were included by adding 50 μL of 0.3
mM dicoumarol solution prior to the addition of the reaction mix. The average
absorbance values from these wells were subtracted from the experimental wells.
NQO1 activity assays in HBEC3-KT were performed essentially as described for
A549 cells with the following modifications. HBEC3-KT cells were seeded at a density
of 2 x 104 cells per well and were cultured overnight. Nrf2 activators (2.5 – 100 nM
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CDDO-Im and 0.625 – 10 µM SFN) or vehicle control (0.05% DMSO) were applied in
fresh media and incubated for 48 h prior to measuring NQO1 activity.
6.12 Cell Proliferation and Imaging
Cell proliferation measurements were conducted through label-free high contrast
brightfield counting via the Cytation 5 Cell Imaging Multi-Mode Reader (BioTek
Instruments, Winooski, VT) every 24 hours. Images were captured at 4x in the brightfield
channel. Two high contrast brightfield images were captured at each time point: an infocus image used for reference, and a defocused image for cell counting. Briefly, cells
were brought into focus using the high contrast brightfield kit. The view line profile tool
was then used to draw a line that crossed cells and background sections of the imaging
field. The focal height was then decreased while observing the line profile to determine
the focal height at which maximum contrast between cell and background brightness was
achieved. This value was then input as an offset from the reference high contrast
brightfield image. Image preprocessing was employed to obtain the best possible
enhancement of contrast, reducing each cell to a single bright spot. In order to achieve
this, the high contrast image was processed with a black background and a 30 μm rolling
ball. This resulted in a dark image with bright spots delineating cells. Gen5 software
applied masks to identify each cell for counting. Cell counts were normalized to area and
expressed as number of cells per mm2.
6.13 MTT Assay For Cell Viability
3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT) assays
were performed in 96-well plates to assess cell metabolic activity as a measurement of
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cell viability. A549 cells were seeded at 1 x 104 per well in a 96-well plates, and
following a 24 h attachment period they were exposed to low and high doses of 3-NBA
(1.25 µM and 10 µM, respectively). After incubation for 24 h, the medium was removed
and 110 l of 0.5 mg/mL MTT (Millipore Sigma, Burlington, MA) diluted in F12K
media was added directly to the wells and the plates incubated for 4 h at 37ºC at 5% CO2.
MTT assays with HBEC3-KT cells were performed under the same conditions as
described for the 3-ABA formation assay. Briefly, 2 x 104 cells were plated in 96-well
plates and were allowed to recover for 24 h to allow cell attachment. HBEC3-KT cells
were then treated with Nrf2 activators (50 nM CDDO-Im and 5 µM SFN) or vehicle
control (0.05% DMSO) for 48 h. Media was then replaced with fresh phenol red-free KSFM containing 1.25 and 10 µM 3-NBA in 0.1% DMSO. After 24 h, the media was
removed and 110 l of 0.5 mg/mL MTT (Millipore Sigma) diluted in K-SFM media was
added directly to the wells and the plates incubated for 4 h at 37ºC at 5% CO2.
Upon completion of the 4 h incubation, the MTT solution was removed and
remaining cells were solubilized in 200 µL DMSO. Formation of the purple formazan
was assessed spectrophotometrically using a Synergy 2 (BioTek) plate reader at 570 nm.
Viability is expressed as a percentage of the vehicle control. Results were analyzed with
a two-way ANOVA to compare cell viability within each 3-NBA dose by Nrf2 knockout
or induction status.

6.14 SYTOX Green Cytotoxicity Assay
Cell death was quantified to assess cytotoxicity due to 3-NBA treatment. A549 cells
were plated as described above and were exposed to low and high doses of 3-NBA (1.25
150

µM and 10 µM, respectively). After exposure to 3-NBA for 24 h, cells were stained with
0.1 µg/mL Hoechst 33342 (Thermo Fisher Scientific, Waltham, MA) to stain living and
dead cells (total cell count) and 100 nM Sytox Green Nuclear Stain (Thermo Fisher
Scientific, Waltham, MA). Sytox Green is impermeable to living cells and stains dead
cells with a compromised membrane. Images were captured at 4x in the DAPI and GFP
channels with a Cytation 5 Cell Imaging Multi-Mode Reader (BioTek Instruments,
Winooski, VT). Image preprocessing was employed to obtain the best possible
enhancement of contrast, as described above with a black background and a 20 μm
rolling ball. Gen5 software applied masks to identify each cell for counting. Cell counts
were normalized to area and expressed as number of cells per mm2. The percentage of
dead cells was calculated as

# 𝑑𝑒𝑎𝑑 𝑐𝑒𝑙𝑙𝑠/𝑚𝑚2
# 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠/𝑚𝑚2

x 100%. Results were analyzed with a two-

way ANOVA to compare cell death within each 3-NBA dose by Nrf2 knockout or
induction status.
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